id	sid	tid	token	lemma	pos
cord-334973-jemeyudi	1	1	key	key	NN
cord-334973-jemeyudi	1	2	:	:	:
cord-334973-jemeyudi	1	3	cord-334973-jemeyudi	cord-334973-jemeyudi	NNP
cord-334973-jemeyudi	2	1	authors	author	NNS
cord-334973-jemeyudi	2	2	:	:	:
cord-334973-jemeyudi	2	3	Wu	Wu	NNP
cord-334973-jemeyudi	2	4	,	,	,
cord-334973-jemeyudi	2	5	Dingye	Dingye	NNP
cord-334973-jemeyudi	2	6	;	;	:
cord-334973-jemeyudi	2	7	Gao	Gao	NNP
cord-334973-jemeyudi	2	8	,	,	,
cord-334973-jemeyudi	3	1	Song	Song	NNP
cord-334973-jemeyudi	3	2	title	title	NN
cord-334973-jemeyudi	3	3	:	:	:
cord-334973-jemeyudi	4	1	Analysis	analysis	NN
cord-334973-jemeyudi	4	2	of	of	IN
cord-334973-jemeyudi	4	3	the	the	DT
cord-334973-jemeyudi	4	4	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	4	5	count	count	NN
cord-334973-jemeyudi	4	6	in	in	IN
cord-334973-jemeyudi	4	7	type	type	NN
cord-334973-jemeyudi	4	8	2	2	CD
cord-334973-jemeyudi	4	9	diabetic	diabetic	JJ
cord-334973-jemeyudi	4	10	patients	patient	NNS
cord-334973-jemeyudi	4	11	with	with	IN
cord-334973-jemeyudi	4	12	coronavirus	coronavirus	NN
cord-334973-jemeyudi	4	13	disease	disease	NN
cord-334973-jemeyudi	4	14	(	(	-LRB-
cord-334973-jemeyudi	4	15	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	4	16	)	)	-RRB-
cord-334973-jemeyudi	4	17	:	:	:
cord-334973-jemeyudi	5	1	A	a	DT
cord-334973-jemeyudi	5	2	retrospective	retrospective	JJ
cord-334973-jemeyudi	5	3	study	study	NN
cord-334973-jemeyudi	5	4	in	in	IN
cord-334973-jemeyudi	5	5	a	a	DT
cord-334973-jemeyudi	5	6	centralized	centralized	JJ
cord-334973-jemeyudi	5	7	treatment	treatment	NN
cord-334973-jemeyudi	5	8	center	center	NN
cord-334973-jemeyudi	5	9	date	date	NN
cord-334973-jemeyudi	5	10	:	:	:
cord-334973-jemeyudi	5	11	2020	2020	CD
cord-334973-jemeyudi	5	12	-	-	HYPH
cord-334973-jemeyudi	5	13	07	07	CD
cord-334973-jemeyudi	5	14	-	-	SYM
cord-334973-jemeyudi	5	15	22	22	CD
cord-334973-jemeyudi	5	16	journal	journal	NN
cord-334973-jemeyudi	5	17	:	:	:
cord-334973-jemeyudi	6	1	Diabetes	diabetes	NN
cord-334973-jemeyudi	6	2	Res	res	NN
cord-334973-jemeyudi	6	3	Clin	Clin	NNP
cord-334973-jemeyudi	6	4	Pract	Pract	NNP
cord-334973-jemeyudi	7	1	DOI	DOI	NNP
cord-334973-jemeyudi	7	2	:	:	:
cord-334973-jemeyudi	7	3	10.1016	10.1016	CD
cord-334973-jemeyudi	7	4	/	/	SYM
cord-334973-jemeyudi	7	5	j.diabres.2020.108340	j.diabres.2020.108340	NN
cord-334973-jemeyudi	7	6	sha	sha	NNP
cord-334973-jemeyudi	7	7	:	:	:
cord-334973-jemeyudi	7	8	52f2fecea9e8d3f0e290aa29a09f2dc1832251ce	52f2fecea9e8d3f0e290aa29a09f2dc1832251ce	CD
cord-334973-jemeyudi	7	9	doc_id	doc_id	CD
cord-334973-jemeyudi	7	10	:	:	:
cord-334973-jemeyudi	7	11	334973	334973	CD
cord-334973-jemeyudi	7	12	cord_uid	cord_uid	NNS
cord-334973-jemeyudi	7	13	:	:	:
cord-334973-jemeyudi	7	14	jemeyudi	jemeyudi	NNP
cord-334973-jemeyudi	7	15	Abstract	Abstract	NNP
cord-334973-jemeyudi	7	16	Objective	Objective	NNP
cord-334973-jemeyudi	8	1	To	to	TO
cord-334973-jemeyudi	8	2	investigate	investigate	VB
cord-334973-jemeyudi	8	3	the	the	DT
cord-334973-jemeyudi	8	4	characteristics	characteristic	NNS
cord-334973-jemeyudi	8	5	of	of	IN
cord-334973-jemeyudi	8	6	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	8	7	in	in	IN
cord-334973-jemeyudi	8	8	type	type	NN
cord-334973-jemeyudi	8	9	2	2	CD
cord-334973-jemeyudi	8	10	diabetic	diabetic	JJ
cord-334973-jemeyudi	8	11	patients	patient	NNS
cord-334973-jemeyudi	8	12	with	with	IN
cord-334973-jemeyudi	8	13	coronavirus	coronavirus	NN
cord-334973-jemeyudi	8	14	disease	disease	NN
cord-334973-jemeyudi	8	15	(	(	-LRB-
cord-334973-jemeyudi	8	16	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	8	17	)	)	-RRB-
cord-334973-jemeyudi	8	18	.	.	.
cord-334973-jemeyudi	9	1	Methods	Methods	NNPS
cord-334973-jemeyudi	9	2	Patients	patient	NNS
cord-334973-jemeyudi	9	3	with	with	IN
cord-334973-jemeyudi	9	4	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	9	5	admitted	admit	VBN
cord-334973-jemeyudi	9	6	to	to	IN
cord-334973-jemeyudi	9	7	hospital	hospital	NN
cord-334973-jemeyudi	9	8	in	in	IN
cord-334973-jemeyudi	9	9	Wuxi	Wuxi	NNP
cord-334973-jemeyudi	9	10	,	,	,
cord-334973-jemeyudi	9	11	China	China	NNP
cord-334973-jemeyudi	9	12	from	from	IN
cord-334973-jemeyudi	9	13	January	January	NNP
cord-334973-jemeyudi	9	14	29	29	CD
cord-334973-jemeyudi	9	15	to	to	IN
cord-334973-jemeyudi	9	16	March	March	NNP
cord-334973-jemeyudi	9	17	15	15	CD
cord-334973-jemeyudi	9	18	were	be	VBD
cord-334973-jemeyudi	9	19	included	include	VBN
cord-334973-jemeyudi	9	20	in	in	IN
cord-334973-jemeyudi	9	21	the	the	DT
cord-334973-jemeyudi	9	22	study	study	NN
cord-334973-jemeyudi	9	23	.	.	.
cord-334973-jemeyudi	10	1	Lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	10	2	were	be	VBD
cord-334973-jemeyudi	10	3	measured	measure	VBN
cord-334973-jemeyudi	10	4	and	and	CC
cord-334973-jemeyudi	10	5	recorded	record	VBN
cord-334973-jemeyudi	10	6	at	at	IN
cord-334973-jemeyudi	10	7	admission	admission	NN
cord-334973-jemeyudi	10	8	and	and	CC
cord-334973-jemeyudi	10	9	during	during	IN
cord-334973-jemeyudi	10	10	treatment	treatment	NN
cord-334973-jemeyudi	10	11	.	.	.
cord-334973-jemeyudi	11	1	Hospitalization	hospitalization	NN
cord-334973-jemeyudi	11	2	days	day	NNS
cord-334973-jemeyudi	11	3	,	,	,
cord-334973-jemeyudi	11	4	severe	severe	JJ
cord-334973-jemeyudi	11	5	acute	acute	JJ
cord-334973-jemeyudi	11	6	respiratory	respiratory	JJ
cord-334973-jemeyudi	11	7	syndrome	syndrome	NN
cord-334973-jemeyudi	11	8	coronavirus	coronavirus	NN
cord-334973-jemeyudi	11	9	2	2	CD
cord-334973-jemeyudi	11	10	(	(	-LRB-
cord-334973-jemeyudi	11	11	SARS	SARS	NNP
cord-334973-jemeyudi	11	12	-	-	HYPH
cord-334973-jemeyudi	11	13	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	11	14	)	)	-RRB-
cord-334973-jemeyudi	11	15	nucleic	nucleic	JJ
cord-334973-jemeyudi	11	16	acid	acid	NN
cord-334973-jemeyudi	11	17	positive	positive	JJ
cord-334973-jemeyudi	11	18	days	day	NNS
cord-334973-jemeyudi	11	19	,	,	,
cord-334973-jemeyudi	11	20	minimal	minimal	JJ
cord-334973-jemeyudi	11	21	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	11	22	count	count	NN
cord-334973-jemeyudi	11	23	,	,	,
cord-334973-jemeyudi	11	24	and	and	CC
cord-334973-jemeyudi	11	25	occurrence	occurrence	NN
cord-334973-jemeyudi	11	26	time	time	NN
cord-334973-jemeyudi	11	27	were	be	VBD
cord-334973-jemeyudi	11	28	collected	collect	VBN
cord-334973-jemeyudi	11	29	and	and	CC
cord-334973-jemeyudi	11	30	comparatively	comparatively	RB
cord-334973-jemeyudi	11	31	analyzed	analyze	VBN
cord-334973-jemeyudi	11	32	.	.	.
cord-334973-jemeyudi	12	1	Correlations	correlation	NNS
cord-334973-jemeyudi	12	2	between	between	IN
cord-334973-jemeyudi	12	3	minimal	minimal	JJ
cord-334973-jemeyudi	12	4	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	12	5	count	count	NN
cord-334973-jemeyudi	12	6	and	and	CC
cord-334973-jemeyudi	12	7	hospitalization	hospitalization	NN
cord-334973-jemeyudi	12	8	days	day	NNS
cord-334973-jemeyudi	12	9	as	as	RB
cord-334973-jemeyudi	12	10	well	well	RB
cord-334973-jemeyudi	12	11	as	as	IN
cord-334973-jemeyudi	12	12	SARS	SARS	NNP
cord-334973-jemeyudi	12	13	-	-	HYPH
cord-334973-jemeyudi	12	14	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	12	15	nucleic	nucleic	JJ
cord-334973-jemeyudi	12	16	acid	acid	NN
cord-334973-jemeyudi	12	17	positive	positive	JJ
cord-334973-jemeyudi	12	18	days	day	NNS
cord-334973-jemeyudi	12	19	were	be	VBD
cord-334973-jemeyudi	12	20	analyzed	analyze	VBN
cord-334973-jemeyudi	12	21	.	.	.
cord-334973-jemeyudi	13	1	Results	result	NNS
cord-334973-jemeyudi	14	1	A	a	DT
cord-334973-jemeyudi	14	2	total	total	NN
cord-334973-jemeyudi	14	3	of	of	IN
cord-334973-jemeyudi	14	4	63	63	CD
cord-334973-jemeyudi	14	5	patients	patient	NNS
cord-334973-jemeyudi	14	6	were	be	VBD
cord-334973-jemeyudi	14	7	included	include	VBN
cord-334973-jemeyudi	14	8	in	in	IN
cord-334973-jemeyudi	14	9	the	the	DT
cord-334973-jemeyudi	14	10	study	study	NN
cord-334973-jemeyudi	14	11	,	,	,
cord-334973-jemeyudi	14	12	with	with	IN
cord-334973-jemeyudi	14	13	16	16	CD
cord-334973-jemeyudi	14	14	in	in	IN
cord-334973-jemeyudi	14	15	the	the	DT
cord-334973-jemeyudi	14	16	diabetic	diabetic	JJ
cord-334973-jemeyudi	14	17	group	group	NN
cord-334973-jemeyudi	14	18	and	and	CC
cord-334973-jemeyudi	14	19	47	47	CD
cord-334973-jemeyudi	14	20	in	in	IN
cord-334973-jemeyudi	14	21	the	the	DT
cord-334973-jemeyudi	14	22	non	non	JJ
cord-334973-jemeyudi	14	23	-	-	JJ
cord-334973-jemeyudi	14	24	diabetic	diabetic	JJ
cord-334973-jemeyudi	14	25	group	group	NN
cord-334973-jemeyudi	14	26	.	.	.
cord-334973-jemeyudi	15	1	After	after	IN
cord-334973-jemeyudi	15	2	adjusting	adjust	VBG
cord-334973-jemeyudi	15	3	for	for	IN
cord-334973-jemeyudi	15	4	potential	potential	JJ
cord-334973-jemeyudi	15	5	confounding	confounding	JJ
cord-334973-jemeyudi	15	6	factors	factor	NNS
cord-334973-jemeyudi	15	7	,	,	,
cord-334973-jemeyudi	15	8	we	-PRON-	PRP
cord-334973-jemeyudi	15	9	observed	observe	VBD
cord-334973-jemeyudi	15	10	lower	low	JJR
cord-334973-jemeyudi	15	11	minimal	minimal	JJ
cord-334973-jemeyudi	15	12	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	15	13	count	count	NN
cord-334973-jemeyudi	15	14	(	(	-LRB-
cord-334973-jemeyudi	15	15	0.67	0.67	CD
cord-334973-jemeyudi	15	16	±	±	CD
cord-334973-jemeyudi	15	17	0.36	0.36	CD
cord-334973-jemeyudi	16	1	*	*	NFP
cord-334973-jemeyudi	16	2	109	109	CD
cord-334973-jemeyudi	16	3	/	/	SYM
cord-334973-jemeyudi	16	4	L	l	NN
cord-334973-jemeyudi	16	5	vs.	vs.	NN
cord-334973-jemeyudi	17	1	1.30	1.30	CD
cord-334973-jemeyudi	17	2	±	±	CD
cord-334973-jemeyudi	17	3	0.54	0.54	CD
cord-334973-jemeyudi	18	1	*	*	NFP
cord-334973-jemeyudi	18	2	109	109	CD
cord-334973-jemeyudi	18	3	/	/	SYM
cord-334973-jemeyudi	18	4	L	L	NNP
cord-334973-jemeyudi	18	5	,	,	,
cord-334973-jemeyudi	18	6	adjusted	adjust	VBN
cord-334973-jemeyudi	18	7	P	p	NN
cord-334973-jemeyudi	18	8	=	=	SYM
cord-334973-jemeyudi	18	9	0.001	0.001	CD
cord-334973-jemeyudi	18	10	)	)	-RRB-
cord-334973-jemeyudi	18	11	,	,	,
cord-334973-jemeyudi	18	12	earlier	early	JJR
cord-334973-jemeyudi	18	13	occurrence	occurrence	NN
cord-334973-jemeyudi	18	14	of	of	IN
cord-334973-jemeyudi	18	15	the	the	DT
cord-334973-jemeyudi	18	16	minimal	minimal	JJ
cord-334973-jemeyudi	18	17	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	18	18	count	count	NN
cord-334973-jemeyudi	18	19	(	(	-LRB-
cord-334973-jemeyudi	18	20	2.68	2.68	CD
cord-334973-jemeyudi	18	21	±	±	CD
cord-334973-jemeyudi	18	22	2.33	2.33	CD
cord-334973-jemeyudi	18	23	days	day	NNS
cord-334973-jemeyudi	18	24	vs.	vs.	IN
cord-334973-jemeyudi	18	25	5.29	5.29	CD
cord-334973-jemeyudi	18	26	±	±	CD
cord-334973-jemeyudi	18	27	4.95	4.95	CD
cord-334973-jemeyudi	18	28	days	day	NNS
cord-334973-jemeyudi	18	29	,	,	,
cord-334973-jemeyudi	18	30	adjusted	adjust	VBN
cord-334973-jemeyudi	18	31	P	p	NN
cord-334973-jemeyudi	18	32	=	=	SYM
cord-334973-jemeyudi	18	33	0.042	0.042	CD
cord-334973-jemeyudi	18	34	)	)	-RRB-
cord-334973-jemeyudi	18	35	,	,	,
cord-334973-jemeyudi	18	36	and	and	CC
cord-334973-jemeyudi	18	37	longer	long	JJR
cord-334973-jemeyudi	18	38	hospitalization	hospitalization	NN
cord-334973-jemeyudi	18	39	time	time	NN
cord-334973-jemeyudi	18	40	(	(	-LRB-
cord-334973-jemeyudi	18	41	20.44	20.44	CD
cord-334973-jemeyudi	18	42	±	±	CD
cord-334973-jemeyudi	18	43	5.24	5.24	CD
cord-334973-jemeyudi	18	44	days	day	NNS
cord-334973-jemeyudi	18	45	vs.	vs.	FW
cord-334973-jemeyudi	18	46	17.11	17.11	CD
cord-334973-jemeyudi	18	47	±	±	CD
cord-334973-jemeyudi	18	48	4.78	4.78	CD
cord-334973-jemeyudi	18	49	days	day	NNS
cord-334973-jemeyudi	18	50	,	,	,
cord-334973-jemeyudi	18	51	adjusted	adjust	VBN
cord-334973-jemeyudi	18	52	P	p	NN
cord-334973-jemeyudi	18	53	=	=	SYM
cord-334973-jemeyudi	18	54	0.047	0.047	CD
cord-334973-jemeyudi	18	55	)	)	-RRB-
cord-334973-jemeyudi	18	56	in	in	IN
cord-334973-jemeyudi	18	57	the	the	DT
cord-334973-jemeyudi	18	58	diabetic	diabetic	JJ
cord-334973-jemeyudi	18	59	group	group	NN
cord-334973-jemeyudi	18	60	than	than	IN
cord-334973-jemeyudi	18	61	in	in	IN
cord-334973-jemeyudi	18	62	the	the	DT
cord-334973-jemeyudi	18	63	non	non	JJ
cord-334973-jemeyudi	18	64	-	-	JJ
cord-334973-jemeyudi	18	65	diabetic	diabetic	JJ
cord-334973-jemeyudi	18	66	group	group	NN
cord-334973-jemeyudi	18	67	.	.	.
cord-334973-jemeyudi	19	1	There	there	EX
cord-334973-jemeyudi	19	2	was	be	VBD
cord-334973-jemeyudi	19	3	a	a	DT
cord-334973-jemeyudi	19	4	negative	negative	JJ
cord-334973-jemeyudi	19	5	correlation	correlation	NN
cord-334973-jemeyudi	19	6	between	between	IN
cord-334973-jemeyudi	19	7	minimal	minimal	JJ
cord-334973-jemeyudi	19	8	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	19	9	count	count	NN
cord-334973-jemeyudi	19	10	and	and	CC
cord-334973-jemeyudi	19	11	hospitalization	hospitalization	NN
cord-334973-jemeyudi	19	12	days	day	NNS
cord-334973-jemeyudi	20	1	(	(	-LRB-
cord-334973-jemeyudi	20	2	R	r	NN
cord-334973-jemeyudi	20	3	=	=	NN
cord-334973-jemeyudi	20	4	-0.600	-0.600	.
cord-334973-jemeyudi	21	1	,	,	,
cord-334973-jemeyudi	21	2	P	p	NN
cord-334973-jemeyudi	21	3	<	<	XX
cord-334973-jemeyudi	21	4	0.05	0.05	CD
cord-334973-jemeyudi	21	5	)	)	-RRB-
cord-334973-jemeyudi	21	6	as	as	RB
cord-334973-jemeyudi	21	7	well	well	RB
cord-334973-jemeyudi	21	8	as	as	IN
cord-334973-jemeyudi	21	9	SARS	SARS	NNP
cord-334973-jemeyudi	21	10	-	-	HYPH
cord-334973-jemeyudi	21	11	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	21	12	nucleic	nucleic	JJ
cord-334973-jemeyudi	21	13	acid	acid	NN
cord-334973-jemeyudi	21	14	positive	positive	JJ
cord-334973-jemeyudi	21	15	days	day	NNS
cord-334973-jemeyudi	21	16	(	(	-LRB-
cord-334973-jemeyudi	22	1	R	r	NN
cord-334973-jemeyudi	22	2	=	=	SYM
cord-334973-jemeyudi	22	3	-0.420	-0.420	NNP
cord-334973-jemeyudi	22	4	,	,	,
cord-334973-jemeyudi	22	5	P	p	NN
cord-334973-jemeyudi	22	6	<	<	XX
cord-334973-jemeyudi	22	7	0.05	0.05	CD
cord-334973-jemeyudi	22	8	)	)	-RRB-
cord-334973-jemeyudi	22	9	.	.	.
cord-334973-jemeyudi	23	1	Conclusions	conclusion	NNS
cord-334973-jemeyudi	24	1	The	the	DT
cord-334973-jemeyudi	24	2	diabetic	diabetic	JJ
cord-334973-jemeyudi	24	3	group	group	NN
cord-334973-jemeyudi	24	4	with	with	IN
cord-334973-jemeyudi	24	5	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	24	6	had	have	VBD
cord-334973-jemeyudi	24	7	lower	low	JJR
cord-334973-jemeyudi	24	8	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	24	9	count	count	NN
cord-334973-jemeyudi	24	10	,	,	,
cord-334973-jemeyudi	24	11	reached	reach	VBD
cord-334973-jemeyudi	24	12	the	the	DT
cord-334973-jemeyudi	24	13	minimal	minimal	JJ
cord-334973-jemeyudi	24	14	count	count	NN
cord-334973-jemeyudi	24	15	faster	fast	RBR
cord-334973-jemeyudi	24	16	,	,	,
cord-334973-jemeyudi	24	17	and	and	CC
cord-334973-jemeyudi	24	18	had	have	VBD
cord-334973-jemeyudi	24	19	longer	long	JJR
cord-334973-jemeyudi	24	20	hospital	hospital	NN
cord-334973-jemeyudi	24	21	stays	stay	NNS
cord-334973-jemeyudi	24	22	than	than	IN
cord-334973-jemeyudi	24	23	the	the	DT
cord-334973-jemeyudi	24	24	non	non	JJ
cord-334973-jemeyudi	24	25	-	-	JJ
cord-334973-jemeyudi	24	26	diabetic	diabetic	JJ
cord-334973-jemeyudi	24	27	group	group	NN
cord-334973-jemeyudi	24	28	.	.	.
cord-334973-jemeyudi	25	1	Hospitalization	hospitalization	NN
cord-334973-jemeyudi	25	2	days	day	NNS
cord-334973-jemeyudi	25	3	and	and	CC
cord-334973-jemeyudi	25	4	SARS	SARS	NNP
cord-334973-jemeyudi	25	5	-	-	HYPH
cord-334973-jemeyudi	25	6	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	25	7	nucleic	nucleic	JJ
cord-334973-jemeyudi	25	8	acid	acid	NN
cord-334973-jemeyudi	25	9	positive	positive	JJ
cord-334973-jemeyudi	25	10	days	day	NNS
cord-334973-jemeyudi	25	11	were	be	VBD
cord-334973-jemeyudi	25	12	negatively	negatively	RB
cord-334973-jemeyudi	25	13	correlated	correlate	VBN
cord-334973-jemeyudi	25	14	with	with	IN
cord-334973-jemeyudi	25	15	the	the	DT
cord-334973-jemeyudi	25	16	minimal	minimal	JJ
cord-334973-jemeyudi	25	17	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	25	18	count	count	NN
cord-334973-jemeyudi	25	19	.	.	.
cord-334973-jemeyudi	26	1	The	the	DT
cord-334973-jemeyudi	26	2	coronavirus	coronavirus	NN
cord-334973-jemeyudi	26	3	disease	disease	NN
cord-334973-jemeyudi	26	4	 	 	_SP
cord-334973-jemeyudi	26	5	December	December	NNP
cord-334973-jemeyudi	26	6	last	last	JJ
cord-334973-jemeyudi	26	7	year	year	NN
cord-334973-jemeyudi	26	8	has	have	VBZ
cord-334973-jemeyudi	26	9	gradually	gradually	RB
cord-334973-jemeyudi	26	10	spread	spread	VBN
cord-334973-jemeyudi	26	11	throughout	throughout	IN
cord-334973-jemeyudi	26	12	the	the	DT
cord-334973-jemeyudi	26	13	world	world	NN
cord-334973-jemeyudi	26	14	.	.	.
cord-334973-jemeyudi	27	1	At	at	IN
cord-334973-jemeyudi	27	2	present	present	NN
cord-334973-jemeyudi	27	3	,	,	,
cord-334973-jemeyudi	27	4	it	-PRON-	PRP
cord-334973-jemeyudi	27	5	has	have	VBZ
cord-334973-jemeyudi	27	6	caused	cause	VBN
cord-334973-jemeyudi	27	7	tens	ten	NNS
cord-334973-jemeyudi	27	8	of	of	IN
cord-334973-jemeyudi	27	9	thousands	thousand	NNS
cord-334973-jemeyudi	27	10	of	of	IN
cord-334973-jemeyudi	27	11	deaths	death	NNS
cord-334973-jemeyudi	27	12	,	,	,
cord-334973-jemeyudi	27	13	and	and	CC
cord-334973-jemeyudi	27	14	there	there	EX
cord-334973-jemeyudi	27	15	are	be	VBP
cord-334973-jemeyudi	27	16	no	no	DT
cord-334973-jemeyudi	27	17	special	special	JJ
cord-334973-jemeyudi	27	18	antiviral	antiviral	JJ
cord-334973-jemeyudi	27	19	drugs	drug	NNS
cord-334973-jemeyudi	27	20	to	to	TO
cord-334973-jemeyudi	27	21	treat	treat	VB
cord-334973-jemeyudi	27	22	it	-PRON-	PRP
cord-334973-jemeyudi	27	23	.	.	.
cord-334973-jemeyudi	28	1	Depending	depend	VBG
cord-334973-jemeyudi	28	2	on	on	IN
cord-334973-jemeyudi	28	3	the	the	DT
cord-334973-jemeyudi	28	4	region	region	NN
cord-334973-jemeyudi	28	5	,	,	,
cord-334973-jemeyudi	28	6	20	20	CD
cord-334973-jemeyudi	28	7	-	-	SYM
cord-334973-jemeyudi	28	8	50	50	CD
cord-334973-jemeyudi	28	9	%	%	NN
cord-334973-jemeyudi	28	10	of	of	IN
cord-334973-jemeyudi	28	11	patients	patient	NNS
cord-334973-jemeyudi	28	12	affected	affect	VBN
cord-334973-jemeyudi	28	13	by	by	IN
cord-334973-jemeyudi	28	14	the	the	DT
cord-334973-jemeyudi	28	15	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	28	16	pandemic	pandemic	NN
cord-334973-jemeyudi	28	17	had	have	VBD
cord-334973-jemeyudi	28	18	diabetes	diabete	NNS
cord-334973-jemeyudi	28	19	[	[	-LRB-
cord-334973-jemeyudi	28	20	1	1	CD
cord-334973-jemeyudi	28	21	]	]	-RRB-
cord-334973-jemeyudi	28	22	.	.	.
cord-334973-jemeyudi	29	1	According	accord	VBG
cord-334973-jemeyudi	29	2	to	to	IN
cord-334973-jemeyudi	29	3	related	related	JJ
cord-334973-jemeyudi	29	4	reports	report	NNS
cord-334973-jemeyudi	29	5	,	,	,
cord-334973-jemeyudi	29	6	patients	patient	NNS
cord-334973-jemeyudi	29	7	with	with	IN
cord-334973-jemeyudi	29	8	diabetes	diabete	NNS
cord-334973-jemeyudi	29	9	are	be	VBP
cord-334973-jemeyudi	29	10	more	more	RBR
cord-334973-jemeyudi	29	11	prone	prone	JJ
cord-334973-jemeyudi	29	12	to	to	IN
cord-334973-jemeyudi	29	13	disease	disease	NN
cord-334973-jemeyudi	29	14	progression	progression	NN
cord-334973-jemeyudi	29	15	than	than	IN
cord-334973-jemeyudi	29	16	those	those	DT
cord-334973-jemeyudi	29	17	without	without	IN
cord-334973-jemeyudi	29	18	diabetes	diabetes	NN
cord-334973-jemeyudi	29	19	[	[	-LRB-
cord-334973-jemeyudi	29	20	2	2	CD
cord-334973-jemeyudi	29	21	,	,	,
cord-334973-jemeyudi	29	22	3	3	CD
cord-334973-jemeyudi	29	23	]	]	-RRB-
cord-334973-jemeyudi	29	24	;	;	:
cord-334973-jemeyudi	29	25	however	however	RB
cord-334973-jemeyudi	29	26	,	,	,
cord-334973-jemeyudi	29	27	the	the	DT
cord-334973-jemeyudi	29	28	mechanism	mechanism	NN
cord-334973-jemeyudi	29	29	is	be	VBZ
cord-334973-jemeyudi	29	30	not	not	RB
cord-334973-jemeyudi	29	31	yet	yet	RB
cord-334973-jemeyudi	29	32	clear	clear	JJ
cord-334973-jemeyudi	29	33	.	.	.
cord-334973-jemeyudi	30	1	Severe	severe	JJ
cord-334973-jemeyudi	30	2	acute	acute	JJ
cord-334973-jemeyudi	30	3	respiratory	respiratory	JJ
cord-334973-jemeyudi	30	4	syndrome	syndrome	NN
cord-334973-jemeyudi	30	5	coronavirus	coronavirus	NN
cord-334973-jemeyudi	30	6	2	2	CD
cord-334973-jemeyudi	31	1	(	(	-LRB-
cord-334973-jemeyudi	31	2	SARS	SARS	NNP
cord-334973-jemeyudi	31	3	-	-	HYPH
cord-334973-jemeyudi	31	4	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	31	5	)	)	-RRB-
cord-334973-jemeyudi	31	6	causes	cause	VBZ
cord-334973-jemeyudi	31	7	a	a	DT
cord-334973-jemeyudi	31	8	reduction	reduction	NN
cord-334973-jemeyudi	31	9	in	in	IN
cord-334973-jemeyudi	31	10	the	the	DT
cord-334973-jemeyudi	31	11	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	31	12	count	count	NN
cord-334973-jemeyudi	31	13	of	of	IN
cord-334973-jemeyudi	31	14	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	31	15	patients	patient	NNS
cord-334973-jemeyudi	31	16	[	[	-LRB-
cord-334973-jemeyudi	31	17	4	4	CD
cord-334973-jemeyudi	31	18	,	,	,
cord-334973-jemeyudi	31	19	5	5	CD
cord-334973-jemeyudi	31	20	]	]	-RRB-
cord-334973-jemeyudi	31	21	.	.	.
cord-334973-jemeyudi	32	1	This	this	DT
cord-334973-jemeyudi	32	2	study	study	NN
cord-334973-jemeyudi	32	3	aims	aim	VBZ
cord-334973-jemeyudi	32	4	to	to	TO
cord-334973-jemeyudi	32	5	analyze	analyze	VB
cord-334973-jemeyudi	32	6	the	the	DT
cord-334973-jemeyudi	32	7	characteristics	characteristic	NNS
cord-334973-jemeyudi	32	8	of	of	IN
cord-334973-jemeyudi	32	9	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	32	10	count	count	NN
cord-334973-jemeyudi	32	11	in	in	IN
cord-334973-jemeyudi	32	12	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	32	13	patients	patient	NNS
cord-334973-jemeyudi	32	14	with	with	IN
cord-334973-jemeyudi	32	15	type	type	NN
cord-334973-jemeyudi	32	16	2	2	CD
cord-334973-jemeyudi	32	17	diabetes	diabetes	NN
cord-334973-jemeyudi	32	18	mellitus	mellitus	NN
cord-334973-jemeyudi	32	19	(	(	-LRB-
cord-334973-jemeyudi	32	20	T2DM	T2DM	NNP
cord-334973-jemeyudi	32	21	)	)	-RRB-
cord-334973-jemeyudi	32	22	.	.	.
cord-334973-jemeyudi	33	1	Adult	adult	NN
cord-334973-jemeyudi	33	2	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	33	3	patients	patient	NNS
cord-334973-jemeyudi	33	4	admitted	admit	VBD
cord-334973-jemeyudi	33	5	to	to	IN
cord-334973-jemeyudi	33	6	the	the	DT
cord-334973-jemeyudi	33	7	Fifth	Fifth	NNP
cord-334973-jemeyudi	33	8	People	People	NNPS
cord-334973-jemeyudi	33	9	's	's	POS
cord-334973-jemeyudi	33	10	Hospital	Hospital	NNP
cord-334973-jemeyudi	33	11	of	of	IN
cord-334973-jemeyudi	33	12	Wuxi	Wuxi	NNP
cord-334973-jemeyudi	33	13	City	City	NNP
cord-334973-jemeyudi	33	14	in	in	IN
cord-334973-jemeyudi	33	15	China	China	NNP
cord-334973-jemeyudi	33	16	from	from	IN
cord-334973-jemeyudi	33	17	January	January	NNP
cord-334973-jemeyudi	33	18	29	29	CD
cord-334973-jemeyudi	33	19	to	to	IN
cord-334973-jemeyudi	33	20	March	March	NNP
cord-334973-jemeyudi	33	21	15	15	CD
cord-334973-jemeyudi	33	22	were	be	VBD
cord-334973-jemeyudi	33	23	included	include	VBN
cord-334973-jemeyudi	33	24	.	.	.
cord-334973-jemeyudi	34	1	Age	age	NN
cord-334973-jemeyudi	34	2	>	>	XX
cord-334973-jemeyudi	34	3	14	14	CD
cord-334973-jemeyudi	34	4	years	year	NNS
cord-334973-jemeyudi	34	5	and	and	CC
cord-334973-jemeyudi	34	6	diagnosis	diagnosis	NN
cord-334973-jemeyudi	34	7	of	of	IN
cord-334973-jemeyudi	34	8	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	34	9	(	(	-LRB-
cord-334973-jemeyudi	34	10	for	for	IN
cord-334973-jemeyudi	34	11	the	the	DT
cord-334973-jemeyudi	34	12	criteria	criterion	NNS
cord-334973-jemeyudi	34	13	,	,	,
cord-334973-jemeyudi	34	14	refer	refer	VB
cord-334973-jemeyudi	34	15	to	to	IN
cord-334973-jemeyudi	34	16	the	the	DT
cord-334973-jemeyudi	34	17	diagnosis	diagnosis	NN
cord-334973-jemeyudi	34	18	and	and	CC
cord-334973-jemeyudi	34	19	treatment	treatment	NN
cord-334973-jemeyudi	34	20	plan	plan	NN
cord-334973-jemeyudi	34	21	for	for	IN
cord-334973-jemeyudi	34	22	the	the	DT
cord-334973-jemeyudi	34	23	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	34	24	in	in	IN
cord-334973-jemeyudi	34	25	China	China	NNP
cord-334973-jemeyudi	34	26	-Trial	-trial	IN
cord-334973-jemeyudi	34	27	Version	Version	NNP
cord-334973-jemeyudi	34	28	7	7	CD
cord-334973-jemeyudi	34	29	;	;	:
cord-334973-jemeyudi	34	30	see	see	VB
cord-334973-jemeyudi	34	31	the	the	DT
cord-334973-jemeyudi	34	32	supplementary	supplementary	JJ
cord-334973-jemeyudi	34	33	file	file	NN
cord-334973-jemeyudi	34	34	for	for	IN
cord-334973-jemeyudi	34	35	details	detail	NNS
cord-334973-jemeyudi	34	36	)	)	-RRB-
cord-334973-jemeyudi	34	37	.	.	.
cord-334973-jemeyudi	35	1	Patients	patient	NNS
cord-334973-jemeyudi	35	2	with	with	IN
cord-334973-jemeyudi	35	3	blood	blood	NN
cord-334973-jemeyudi	35	4	diseases	disease	NNS
cord-334973-jemeyudi	35	5	,	,	,
cord-334973-jemeyudi	35	6	AIDS	AIDS	NNP
cord-334973-jemeyudi	35	7	,	,	,
cord-334973-jemeyudi	35	8	and	and	CC
cord-334973-jemeyudi	35	9	T1DM	T1DM	NNP
cord-334973-jemeyudi	35	10	;	;	:
cord-334973-jemeyudi	35	11	patients	patient	NNS
cord-334973-jemeyudi	35	12	without	without	IN
cord-334973-jemeyudi	35	13	incomplete	incomplete	JJ
cord-334973-jemeyudi	35	14	data	datum	NNS
cord-334973-jemeyudi	35	15	.	.	.
cord-334973-jemeyudi	36	1	Data	datum	NNS
cord-334973-jemeyudi	36	2	pertaining	pertain	VBG
cord-334973-jemeyudi	36	3	to	to	IN
cord-334973-jemeyudi	36	4	gender	gender	NN
cord-334973-jemeyudi	36	5	,	,	,
cord-334973-jemeyudi	36	6	age	age	NN
cord-334973-jemeyudi	36	7	,	,	,
cord-334973-jemeyudi	36	8	T2DM	T2DM	NNP
cord-334973-jemeyudi	36	9	status	status	NN
cord-334973-jemeyudi	36	10	,	,	,
cord-334973-jemeyudi	36	11	body	body	NN
cord-334973-jemeyudi	36	12	mass	mass	NN
cord-334973-jemeyudi	36	13	index	index	NN
cord-334973-jemeyudi	36	14	(	(	-LRB-
cord-334973-jemeyudi	36	15	BMI	BMI	NNP
cord-334973-jemeyudi	36	16	)	)	-RRB-
cord-334973-jemeyudi	36	17	,	,	,
cord-334973-jemeyudi	36	18	systolic	systolic	JJ
cord-334973-jemeyudi	36	19	blood	blood	NN
cord-334973-jemeyudi	36	20	pressure	pressure	NN
cord-334973-jemeyudi	36	21	(	(	-LRB-
cord-334973-jemeyudi	36	22	SBP	SBP	NNP
cord-334973-jemeyudi	36	23	)	)	-RRB-
cord-334973-jemeyudi	36	24	,	,	,
cord-334973-jemeyudi	36	25	and	and	CC
cord-334973-jemeyudi	36	26	diastolic	diastolic	JJ
cord-334973-jemeyudi	36	27	blood	blood	NN
cord-334973-jemeyudi	36	28	pressure	pressure	NN
cord-334973-jemeyudi	36	29	(	(	-LRB-
cord-334973-jemeyudi	36	30	DBP	DBP	NNP
cord-334973-jemeyudi	36	31	)	)	-RRB-
cord-334973-jemeyudi	36	32	were	be	VBD
cord-334973-jemeyudi	36	33	obtained	obtain	VBN
cord-334973-jemeyudi	36	34	at	at	IN
cord-334973-jemeyudi	36	35	the	the	DT
cord-334973-jemeyudi	36	36	time	time	NN
cord-334973-jemeyudi	36	37	of	of	IN
cord-334973-jemeyudi	36	38	admission	admission	NN
cord-334973-jemeyudi	36	39	.	.	.
cord-334973-jemeyudi	37	1	Data	datum	NNS
cord-334973-jemeyudi	37	2	on	on	IN
cord-334973-jemeyudi	37	3	alanine	alanine	NN
cord-334973-jemeyudi	37	4	aminotransferase	aminotransferase	NN
cord-334973-jemeyudi	37	5	(	(	-LRB-
cord-334973-jemeyudi	37	6	ALT	ALT	NNP
cord-334973-jemeyudi	37	7	)	)	-RRB-
cord-334973-jemeyudi	37	8	,	,	,
cord-334973-jemeyudi	37	9	aspartate	aspartate	NN
cord-334973-jemeyudi	37	10	aminotransferase	aminotransferase	NN
cord-334973-jemeyudi	37	11	(	(	-LRB-
cord-334973-jemeyudi	37	12	AST	AST	NNP
cord-334973-jemeyudi	37	13	)	)	-RRB-
cord-334973-jemeyudi	37	14	,	,	.
cord-334973-jemeyudi	38	1	creatinine	creatinine	NNP
cord-334973-jemeyudi	38	2	(	(	-LRB-
cord-334973-jemeyudi	38	3	Cr	Cr	NNP
cord-334973-jemeyudi	38	4	)	)	-RRB-
cord-334973-jemeyudi	38	5	,	,	,
cord-334973-jemeyudi	38	6	and	and	CC
cord-334973-jemeyudi	38	7	fasting	fast	VBG
cord-334973-jemeyudi	38	8	glucose	glucose	NN
cord-334973-jemeyudi	38	9	were	be	VBD
cord-334973-jemeyudi	38	10	obtained	obtain	VBN
cord-334973-jemeyudi	38	11	the	the	DT
cord-334973-jemeyudi	38	12	next	next	JJ
cord-334973-jemeyudi	38	13	morning	morning	NN
cord-334973-jemeyudi	38	14	after	after	IN
cord-334973-jemeyudi	38	15	admission	admission	NN
cord-334973-jemeyudi	38	16	.	.	.
cord-334973-jemeyudi	39	1	White	white	JJ
cord-334973-jemeyudi	39	2	blood	blood	NN
cord-334973-jemeyudi	39	3	cell	cell	NN
cord-334973-jemeyudi	39	4	count	count	NN
cord-334973-jemeyudi	39	5	(	(	-LRB-
cord-334973-jemeyudi	39	6	WBC	WBC	NNP
cord-334973-jemeyudi	39	7	)	)	-RRB-
cord-334973-jemeyudi	39	8	,	,	,
cord-334973-jemeyudi	39	9	C	C	NNP
cord-334973-jemeyudi	39	10	-	-	HYPH
cord-334973-jemeyudi	39	11	reactive	reactive	JJ
cord-334973-jemeyudi	39	12	protein	protein	NN
cord-334973-jemeyudi	39	13	(	(	-LRB-
cord-334973-jemeyudi	39	14	CRP	CRP	NNP
cord-334973-jemeyudi	39	15	)	)	-RRB-
cord-334973-jemeyudi	39	16	and	and	CC
cord-334973-jemeyudi	39	17	Lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	39	18	were	be	VBD
cord-334973-jemeyudi	39	19	measured	measure	VBN
cord-334973-jemeyudi	39	20	at	at	IN
cord-334973-jemeyudi	39	21	admission	admission	NN
cord-334973-jemeyudi	39	22	and	and	CC
cord-334973-jemeyudi	39	23	during	during	IN
cord-334973-jemeyudi	39	24	treatment	treatment	NN
cord-334973-jemeyudi	39	25	.	.	.
cord-334973-jemeyudi	40	1	Data	datum	NNS
cord-334973-jemeyudi	40	2	on	on	IN
cord-334973-jemeyudi	40	3	maximal	maximal	JJ
cord-334973-jemeyudi	40	4	and	and	CC
cord-334973-jemeyudi	40	5	minimal	minimal	JJ
cord-334973-jemeyudi	40	6	WBC	WBC	NNP
cord-334973-jemeyudi	40	7	,	,	,
cord-334973-jemeyudi	40	8	maximal	maximal	JJ
cord-334973-jemeyudi	40	9	CRP	crp	NN
cord-334973-jemeyudi	40	10	,	,	,
cord-334973-jemeyudi	40	11	minimal	minimal	JJ
cord-334973-jemeyudi	40	12	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	40	13	count	count	NN
cord-334973-jemeyudi	40	14	and	and	CC
cord-334973-jemeyudi	40	15	emergence	emergence	NN
cord-334973-jemeyudi	40	16	time	time	NN
cord-334973-jemeyudi	40	17	,	,	,
cord-334973-jemeyudi	40	18	hospitalization	hospitalization	NN
cord-334973-jemeyudi	40	19	days	day	NNS
cord-334973-jemeyudi	40	20	,	,	,
cord-334973-jemeyudi	40	21	and	and	CC
cord-334973-jemeyudi	40	22	SARS	SARS	NNP
cord-334973-jemeyudi	40	23	-	-	HYPH
cord-334973-jemeyudi	40	24	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	40	25	nucleic	nucleic	JJ
cord-334973-jemeyudi	40	26	acid	acid	NN
cord-334973-jemeyudi	40	27	positive	positive	JJ
cord-334973-jemeyudi	40	28	days	day	NNS
cord-334973-jemeyudi	40	29	were	be	VBD
cord-334973-jemeyudi	40	30	recorded	record	VBN
cord-334973-jemeyudi	40	31	during	during	IN
cord-334973-jemeyudi	40	32	hospitalization	hospitalization	NN
cord-334973-jemeyudi	40	33	.	.	.
cord-334973-jemeyudi	41	1	According	accord	VBG
cord-334973-jemeyudi	41	2	to	to	IN
cord-334973-jemeyudi	41	3	our	-PRON-	PRP$
cord-334973-jemeyudi	41	4	medical	medical	JJ
cord-334973-jemeyudi	41	5	practice	practice	NN
cord-334973-jemeyudi	41	6	,	,	,
cord-334973-jemeyudi	41	7	each	each	DT
cord-334973-jemeyudi	41	8	patient	patient	NN
cord-334973-jemeyudi	41	9	's	's	POS
cord-334973-jemeyudi	41	10	WBC	WBC	NNP
cord-334973-jemeyudi	41	11	count	count	NN
cord-334973-jemeyudi	41	12	,	,	,
cord-334973-jemeyudi	41	13	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	41	14	count	count	NN
cord-334973-jemeyudi	41	15	,	,	,
cord-334973-jemeyudi	41	16	and	and	CC
cord-334973-jemeyudi	41	17	CRP	CRP	NNP
cord-334973-jemeyudi	41	18	were	be	VBD
cord-334973-jemeyudi	41	19	measured	measure	VBN
cord-334973-jemeyudi	41	20	and	and	CC
cord-334973-jemeyudi	41	21	recorded	record	VBD
cord-334973-jemeyudi	41	22	at	at	IN
cord-334973-jemeyudi	41	23	admission	admission	NN
cord-334973-jemeyudi	41	24	and	and	CC
cord-334973-jemeyudi	41	25	during	during	IN
cord-334973-jemeyudi	41	26	treatment	treatment	NN
cord-334973-jemeyudi	41	27	.	.	.
cord-334973-jemeyudi	41	28	.	.	.
cord-334973-jemeyudi	42	1	SARS	SARS	NNP
cord-334973-jemeyudi	42	2	-	-	HYPH
cord-334973-jemeyudi	42	3	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	42	4	nucleic	nucleic	JJ
cord-334973-jemeyudi	42	5	acid	acid	NN
cord-334973-jemeyudi	42	6	tests	test	NNS
cord-334973-jemeyudi	42	7	with	with	IN
cord-334973-jemeyudi	42	8	nose	nose	NN
cord-334973-jemeyudi	42	9	and	and	CC
cord-334973-jemeyudi	42	10	throat	throat	NN
cord-334973-jemeyudi	42	11	swabs	swab	NNS
cord-334973-jemeyudi	42	12	were	be	VBD
cord-334973-jemeyudi	42	13	conducted	conduct	VBN
cord-334973-jemeyudi	42	14	daily	daily	JJ
cord-334973-jemeyudi	42	15	7	7	CD
cord-334973-jemeyudi	42	16	days	day	NNS
cord-334973-jemeyudi	42	17	after	after	IN
cord-334973-jemeyudi	42	18	admission	admission	NN
cord-334973-jemeyudi	42	19	.	.	.
cord-334973-jemeyudi	43	1	Viral	viral	JJ
cord-334973-jemeyudi	43	2	nucleic	nucleic	JJ
cord-334973-jemeyudi	43	3	acid	acid	NN
cord-334973-jemeyudi	43	4	tests	test	NNS
cord-334973-jemeyudi	43	5	were	be	VBD
cord-334973-jemeyudi	43	6	stopped	stop	VBN
cord-334973-jemeyudi	43	7	after	after	IN
cord-334973-jemeyudi	43	8	detection	detection	NN
cord-334973-jemeyudi	43	9	of	of	IN
cord-334973-jemeyudi	43	10	negative	negative	JJ
cord-334973-jemeyudi	43	11	results	result	NNS
cord-334973-jemeyudi	43	12	on	on	IN
cord-334973-jemeyudi	43	13	2	2	CD
cord-334973-jemeyudi	43	14	consecutive	consecutive	JJ
cord-334973-jemeyudi	43	15	days	day	NNS
cord-334973-jemeyudi	43	16	.	.	.
cord-334973-jemeyudi	44	1	SARS	SARS	NNP
cord-334973-jemeyudi	44	2	-	-	HYPH
cord-334973-jemeyudi	44	3	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	44	4	nucleic	nucleic	JJ
cord-334973-jemeyudi	44	5	acid	acid	NN
cord-334973-jemeyudi	44	6	positive	positive	JJ
cord-334973-jemeyudi	44	7	days	day	NNS
cord-334973-jemeyudi	44	8	refers	refer	VBZ
cord-334973-jemeyudi	44	9	to	to	IN
cord-334973-jemeyudi	44	10	the	the	DT
cord-334973-jemeyudi	44	11	time	time	NN
cord-334973-jemeyudi	44	12	from	from	IN
cord-334973-jemeyudi	44	13	the	the	DT
cord-334973-jemeyudi	44	14	first	first	JJ
cord-334973-jemeyudi	44	15	to	to	IN
cord-334973-jemeyudi	44	16	the	the	DT
cord-334973-jemeyudi	44	17	last	last	JJ
cord-334973-jemeyudi	44	18	positive	positive	JJ
cord-334973-jemeyudi	44	19	results	result	NNS
cord-334973-jemeyudi	44	20	.	.	.
cord-334973-jemeyudi	45	1	This	this	DT
cord-334973-jemeyudi	45	2	study	study	NN
cord-334973-jemeyudi	45	3	used	use	VBD
cord-334973-jemeyudi	45	4	retrospective	retrospective	JJ
cord-334973-jemeyudi	45	5	case	case	NN
cord-334973-jemeyudi	45	6	notes	note	NNS
cord-334973-jemeyudi	45	7	,	,	,
cord-334973-jemeyudi	45	8	so	so	IN
cord-334973-jemeyudi	45	9	the	the	DT
cord-334973-jemeyudi	45	10	requirement	requirement	NN
cord-334973-jemeyudi	45	11	for	for	IN
cord-334973-jemeyudi	45	12	ethical	ethical	JJ
cord-334973-jemeyudi	45	13	approval	approval	NN
cord-334973-jemeyudi	45	14	was	be	VBD
cord-334973-jemeyudi	45	15	deemed	deem	VBN
cord-334973-jemeyudi	45	16	unnecessary	unnecessary	JJ
cord-334973-jemeyudi	45	17	.	.	.
cord-334973-jemeyudi	46	1	Patients	patient	NNS
cord-334973-jemeyudi	46	2	were	be	VBD
cord-334973-jemeyudi	46	3	divided	divide	VBN
cord-334973-jemeyudi	46	4	into	into	IN
cord-334973-jemeyudi	46	5	diabetes	diabetes	NN
cord-334973-jemeyudi	46	6	and	and	CC
cord-334973-jemeyudi	46	7	non	non	JJ
cord-334973-jemeyudi	46	8	-	-	JJ
cord-334973-jemeyudi	46	9	diabetes	diabetes	JJ
cord-334973-jemeyudi	46	10	groups	group	NNS
cord-334973-jemeyudi	46	11	.	.	.
cord-334973-jemeyudi	47	1	The	the	DT
cord-334973-jemeyudi	47	2	differences	difference	NNS
cord-334973-jemeyudi	47	3	in	in	IN
cord-334973-jemeyudi	47	4	general	general	JJ
cord-334973-jemeyudi	47	5	conditions	condition	NNS
cord-334973-jemeyudi	47	6	such	such	JJ
cord-334973-jemeyudi	47	7	as	as	IN
cord-334973-jemeyudi	47	8	gender	gender	NN
cord-334973-jemeyudi	47	9	,	,	,
cord-334973-jemeyudi	47	10	age	age	NN
cord-334973-jemeyudi	47	11	,	,	,
cord-334973-jemeyudi	47	12	BMI	BMI	NNP
cord-334973-jemeyudi	47	13	,	,	,
cord-334973-jemeyudi	47	14	SBP	SBP	NNP
cord-334973-jemeyudi	47	15	,	,	,
cord-334973-jemeyudi	47	16	DBP	DBP	NNP
cord-334973-jemeyudi	47	17	,	,	,
cord-334973-jemeyudi	47	18	ALT	ALT	NNP
cord-334973-jemeyudi	47	19	,	,	,
cord-334973-jemeyudi	47	20	AST	AST	NNP
cord-334973-jemeyudi	47	21	,	,	,
cord-334973-jemeyudi	47	22	and	and	CC
cord-334973-jemeyudi	47	23	Cr	Cr	NNP
cord-334973-jemeyudi	47	24	were	be	VBD
cord-334973-jemeyudi	47	25	observed	observe	VBN
cord-334973-jemeyudi	47	26	between	between	IN
cord-334973-jemeyudi	47	27	the	the	DT
cord-334973-jemeyudi	47	28	two	two	CD
cord-334973-jemeyudi	47	29	groups	group	NNS
cord-334973-jemeyudi	47	30	.	.	.
cord-334973-jemeyudi	48	1	The	the	DT
cord-334973-jemeyudi	48	2	differences	difference	NNS
cord-334973-jemeyudi	48	3	in	in	IN
cord-334973-jemeyudi	48	4	maximal	maximal	JJ
cord-334973-jemeyudi	48	5	and	and	CC
cord-334973-jemeyudi	48	6	minimal	minimal	JJ
cord-334973-jemeyudi	48	7	WBC	WBC	NNP
cord-334973-jemeyudi	48	8	count	count	NN
cord-334973-jemeyudi	48	9	,	,	,
cord-334973-jemeyudi	48	10	maximal	maximal	JJ
cord-334973-jemeyudi	48	11	CRP	crp	NN
cord-334973-jemeyudi	48	12	level	level	NN
cord-334973-jemeyudi	48	13	,	,	,
cord-334973-jemeyudi	48	14	time	time	NN
cord-334973-jemeyudi	48	15	and	and	CC
cord-334973-jemeyudi	48	16	value	value	NN
cord-334973-jemeyudi	48	17	of	of	IN
cord-334973-jemeyudi	48	18	the	the	DT
cord-334973-jemeyudi	48	19	minimal	minimal	JJ
cord-334973-jemeyudi	48	20	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	48	21	count	count	NN
cord-334973-jemeyudi	48	22	,	,	,
cord-334973-jemeyudi	48	23	hospitalization	hospitalization	NN
cord-334973-jemeyudi	48	24	days	day	NNS
cord-334973-jemeyudi	48	25	,	,	,
cord-334973-jemeyudi	48	26	and	and	CC
cord-334973-jemeyudi	48	27	SARS	SARS	NNP
cord-334973-jemeyudi	48	28	-	-	HYPH
cord-334973-jemeyudi	48	29	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	48	30	nucleic	nucleic	JJ
cord-334973-jemeyudi	48	31	acid	acid	NN
cord-334973-jemeyudi	48	32	positive	positive	JJ
cord-334973-jemeyudi	48	33	days	day	NNS
cord-334973-jemeyudi	48	34	between	between	IN
cord-334973-jemeyudi	48	35	the	the	DT
cord-334973-jemeyudi	48	36	two	two	CD
cord-334973-jemeyudi	48	37	groups	group	NNS
cord-334973-jemeyudi	48	38	were	be	VBD
cord-334973-jemeyudi	48	39	analyzed	analyze	VBN
cord-334973-jemeyudi	48	40	.	.	.
cord-334973-jemeyudi	49	1	Correlations	correlation	NNS
cord-334973-jemeyudi	49	2	between	between	IN
cord-334973-jemeyudi	49	3	minimal	minimal	JJ
cord-334973-jemeyudi	49	4	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	49	5	count	count	NN
cord-334973-jemeyudi	49	6	and	and	CC
cord-334973-jemeyudi	49	7	hospitalization	hospitalization	NN
cord-334973-jemeyudi	49	8	days	day	NNS
cord-334973-jemeyudi	49	9	as	as	RB
cord-334973-jemeyudi	49	10	well	well	RB
cord-334973-jemeyudi	49	11	as	as	IN
cord-334973-jemeyudi	49	12	SARS	SARS	NNP
cord-334973-jemeyudi	49	13	-	-	HYPH
cord-334973-jemeyudi	49	14	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	49	15	nucleic	nucleic	JJ
cord-334973-jemeyudi	49	16	acid	acid	NN
cord-334973-jemeyudi	49	17	positive	positive	JJ
cord-334973-jemeyudi	49	18	days	day	NNS
cord-334973-jemeyudi	49	19	were	be	VBD
cord-334973-jemeyudi	49	20	analyzed	analyze	VBN
cord-334973-jemeyudi	49	21	.	.	.
cord-334973-jemeyudi	50	1	IBM	IBM	NNP
cord-334973-jemeyudi	50	2	SPSS	SPSS	NNP
cord-334973-jemeyudi	50	3	statistics	statistic	NNS
cord-334973-jemeyudi	50	4	23	23	CD
cord-334973-jemeyudi	50	5	software	software	NN
cord-334973-jemeyudi	50	6	was	be	VBD
cord-334973-jemeyudi	50	7	used	use	VBN
cord-334973-jemeyudi	50	8	for	for	IN
cord-334973-jemeyudi	50	9	statistical	statistical	JJ
cord-334973-jemeyudi	50	10	analysis	analysis	NN
cord-334973-jemeyudi	50	11	.	.	.
cord-334973-jemeyudi	51	1	Continuous	continuous	JJ
cord-334973-jemeyudi	51	2	variables	variable	NNS
cord-334973-jemeyudi	51	3	with	with	IN
cord-334973-jemeyudi	51	4	normal	normal	JJ
cord-334973-jemeyudi	51	5	distribution	distribution	NN
cord-334973-jemeyudi	51	6	were	be	VBD
cord-334973-jemeyudi	51	7	presented	present	VBN
cord-334973-jemeyudi	51	8	as	as	IN
cord-334973-jemeyudi	51	9	mean	mean	JJ
cord-334973-jemeyudi	51	10	±	±	NNP
cord-334973-jemeyudi	51	11	standard	standard	JJ
cord-334973-jemeyudi	51	12	deviation	deviation	NN
cord-334973-jemeyudi	51	13	(	(	-LRB-
cord-334973-jemeyudi	51	14	M±SD	M±SD	NNP
cord-334973-jemeyudi	51	15	)	)	-RRB-
cord-334973-jemeyudi	51	16	,	,	,
cord-334973-jemeyudi	51	17	and	and	CC
cord-334973-jemeyudi	51	18	differences	difference	NNS
cord-334973-jemeyudi	51	19	between	between	IN
cord-334973-jemeyudi	51	20	the	the	DT
cord-334973-jemeyudi	51	21	two	two	CD
cord-334973-jemeyudi	51	22	groups	group	NNS
cord-334973-jemeyudi	51	23	were	be	VBD
cord-334973-jemeyudi	51	24	determined	determine	VBN
cord-334973-jemeyudi	51	25	by	by	IN
cord-334973-jemeyudi	51	26	one	one	CD
cord-334973-jemeyudi	51	27	-	-	HYPH
cord-334973-jemeyudi	51	28	way	way	NN
cord-334973-jemeyudi	51	29	ANOVA	anova	NN
cord-334973-jemeyudi	51	30	test	test	NN
cord-334973-jemeyudi	51	31	.	.	.
cord-334973-jemeyudi	52	1	Continuous	continuous	JJ
cord-334973-jemeyudi	52	2	variables	variable	NNS
cord-334973-jemeyudi	52	3	with	with	IN
cord-334973-jemeyudi	52	4	nonnormal	nonnormal	NN
cord-334973-jemeyudi	52	5	distribution	distribution	NN
cord-334973-jemeyudi	52	6	were	be	VBD
cord-334973-jemeyudi	52	7	presented	present	VBN
cord-334973-jemeyudi	52	8	as	as	IN
cord-334973-jemeyudi	52	9	median	median	NN
cord-334973-jemeyudi	52	10	with	with	IN
cord-334973-jemeyudi	52	11	inter	inter	JJ
cord-334973-jemeyudi	52	12	-	-	JJ
cord-334973-jemeyudi	52	13	quartile	quartile	JJ
cord-334973-jemeyudi	52	14	range	range	NN
cord-334973-jemeyudi	52	15	(	(	-LRB-
cord-334973-jemeyudi	52	16	IQR	IQR	NNP
cord-334973-jemeyudi	52	17	)	)	-RRB-
cord-334973-jemeyudi	52	18	,	,	,
cord-334973-jemeyudi	52	19	and	and	CC
cord-334973-jemeyudi	52	20	differences	difference	NNS
cord-334973-jemeyudi	52	21	between	between	IN
cord-334973-jemeyudi	52	22	the	the	DT
cord-334973-jemeyudi	52	23	two	two	CD
cord-334973-jemeyudi	52	24	groups	group	NNS
cord-334973-jemeyudi	52	25	were	be	VBD
cord-334973-jemeyudi	52	26	determined	determine	VBN
cord-334973-jemeyudi	52	27	by	by	IN
cord-334973-jemeyudi	52	28	a	a	DT
cord-334973-jemeyudi	52	29	rank	rank	NN
cord-334973-jemeyudi	52	30	test	test	NN
cord-334973-jemeyudi	52	31	.	.	.
cord-334973-jemeyudi	53	1	In	in	IN
cord-334973-jemeyudi	53	2	addition	addition	NN
cord-334973-jemeyudi	53	3	,	,	,
cord-334973-jemeyudi	53	4	a	a	DT
cord-334973-jemeyudi	53	5	multiple	multiple	JJ
cord-334973-jemeyudi	53	6	linear	linear	JJ
cord-334973-jemeyudi	53	7	regression	regression	NN
cord-334973-jemeyudi	53	8	model	model	NN
cord-334973-jemeyudi	53	9	was	be	VBD
cord-334973-jemeyudi	53	10	used	use	VBN
cord-334973-jemeyudi	53	11	to	to	TO
cord-334973-jemeyudi	53	12	analyze	analyze	VB
cord-334973-jemeyudi	53	13	the	the	DT
cord-334973-jemeyudi	53	14	effect	effect	NN
cord-334973-jemeyudi	53	15	of	of	IN
cord-334973-jemeyudi	53	16	diabetes	diabetes	NN
cord-334973-jemeyudi	53	17	on	on	IN
cord-334973-jemeyudi	53	18	minimal	minimal	JJ
cord-334973-jemeyudi	53	19	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	53	20	count	count	NN
cord-334973-jemeyudi	53	21	and	and	CC
cord-334973-jemeyudi	53	22	its	-PRON-	PRP$
cord-334973-jemeyudi	53	23	emergence	emergence	NN
cord-334973-jemeyudi	53	24	time	time	NN
cord-334973-jemeyudi	53	25	,	,	,
cord-334973-jemeyudi	53	26	patient	patient	NN
cord-334973-jemeyudi	53	27	's	's	POS
cord-334973-jemeyudi	53	28	hospitalization	hospitalization	NN
cord-334973-jemeyudi	53	29	days	day	NNS
cord-334973-jemeyudi	53	30	,	,	,
cord-334973-jemeyudi	53	31	and	and	CC
cord-334973-jemeyudi	53	32	SARS	SARS	NNP
cord-334973-jemeyudi	53	33	-	-	HYPH
cord-334973-jemeyudi	53	34	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	53	35	nucleic	nucleic	JJ
cord-334973-jemeyudi	53	36	acid	acid	NN
cord-334973-jemeyudi	53	37	positive	positive	JJ
cord-334973-jemeyudi	53	38	days	day	NNS
cord-334973-jemeyudi	53	39	by	by	IN
cord-334973-jemeyudi	53	40	adjusting	adjust	VBG
cord-334973-jemeyudi	53	41	for	for	IN
cord-334973-jemeyudi	53	42	potential	potential	JJ
cord-334973-jemeyudi	53	43	confounding	confounding	JJ
cord-334973-jemeyudi	53	44	factors	factor	NNS
cord-334973-jemeyudi	53	45	including	include	VBG
cord-334973-jemeyudi	53	46	age	age	NN
cord-334973-jemeyudi	53	47	;	;	:
cord-334973-jemeyudi	53	48	gender	gender	NN
cord-334973-jemeyudi	53	49	;	;	:
cord-334973-jemeyudi	53	50	BMI	bmi	NN
cord-334973-jemeyudi	53	51	;	;	:
cord-334973-jemeyudi	53	52	SBP	SBP	NNP
cord-334973-jemeyudi	53	53	;	;	:
cord-334973-jemeyudi	53	54	DBP	DBP	NNP
cord-334973-jemeyudi	53	55	;	;	:
cord-334973-jemeyudi	53	56	and	and	CC
cord-334973-jemeyudi	53	57	ALT	ALT	NNP
cord-334973-jemeyudi	53	58	,	,	,
cord-334973-jemeyudi	53	59	AST	AST	NNP
cord-334973-jemeyudi	53	60	,	,	,
cord-334973-jemeyudi	53	61	and	and	CC
cord-334973-jemeyudi	53	62	Cr	cr	NN
cord-334973-jemeyudi	53	63	levels	level	NNS
cord-334973-jemeyudi	53	64	.	.	.
cord-334973-jemeyudi	54	1	Categorical	categorical	JJ
cord-334973-jemeyudi	54	2	variables	variable	NNS
cord-334973-jemeyudi	54	3	were	be	VBD
cord-334973-jemeyudi	54	4	described	describe	VBN
cord-334973-jemeyudi	54	5	as	as	IN
cord-334973-jemeyudi	54	6	number	number	NN
cord-334973-jemeyudi	54	7	or	or	CC
cord-334973-jemeyudi	54	8	rate	rate	NN
cord-334973-jemeyudi	54	9	,	,	,
cord-334973-jemeyudi	54	10	and	and	CC
cord-334973-jemeyudi	54	11	differences	difference	NNS
cord-334973-jemeyudi	54	12	between	between	IN
cord-334973-jemeyudi	54	13	the	the	DT
cord-334973-jemeyudi	54	14	two	two	CD
cord-334973-jemeyudi	54	15	groups	group	NNS
cord-334973-jemeyudi	54	16	were	be	VBD
cord-334973-jemeyudi	54	17	determined	determine	VBN
cord-334973-jemeyudi	54	18	by	by	IN
cord-334973-jemeyudi	54	19	a	a	DT
cord-334973-jemeyudi	54	20	Chi	Chi	NNP
cord-334973-jemeyudi	54	21	-	-	HYPH
cord-334973-jemeyudi	54	22	square	square	JJ
cord-334973-jemeyudi	54	23	test	test	NN
cord-334973-jemeyudi	54	24	.	.	.
cord-334973-jemeyudi	55	1	The	the	DT
cord-334973-jemeyudi	55	2	correlation	correlation	NN
cord-334973-jemeyudi	55	3	between	between	IN
cord-334973-jemeyudi	55	4	the	the	DT
cord-334973-jemeyudi	55	5	two	two	CD
cord-334973-jemeyudi	55	6	groups	group	NNS
cord-334973-jemeyudi	55	7	was	be	VBD
cord-334973-jemeyudi	55	8	observed	observe	VBN
cord-334973-jemeyudi	55	9	using	use	VBG
cord-334973-jemeyudi	55	10	a	a	DT
cord-334973-jemeyudi	55	11	scatter	scatter	NN
cord-334973-jemeyudi	55	12	chart	chart	NN
cord-334973-jemeyudi	55	13	.	.	.
cord-334973-jemeyudi	56	1	When	when	WRB
cord-334973-jemeyudi	56	2	linear	linear	JJ
cord-334973-jemeyudi	56	3	correlation	correlation	NN
cord-334973-jemeyudi	56	4	between	between	IN
cord-334973-jemeyudi	56	5	two	two	CD
cord-334973-jemeyudi	56	6	continuous	continuous	JJ
cord-334973-jemeyudi	56	7	variables	variable	NNS
cord-334973-jemeyudi	56	8	was	be	VBD
cord-334973-jemeyudi	56	9	observed	observe	VBN
cord-334973-jemeyudi	56	10	,	,	,
cord-334973-jemeyudi	56	11	Pearson	Pearson	NNP
cord-334973-jemeyudi	56	12	's	's	POS
cord-334973-jemeyudi	56	13	product	product	NN
cord-334973-jemeyudi	56	14	-	-	HYPH
cord-334973-jemeyudi	56	15	moment	moment	NN
cord-334973-jemeyudi	56	16	correlation	correlation	NN
cord-334973-jemeyudi	56	17	coefficient	coefficient	NN
cord-334973-jemeyudi	56	18	was	be	VBD
cord-334973-jemeyudi	56	19	used	use	VBN
cord-334973-jemeyudi	56	20	.	.	.
cord-334973-jemeyudi	57	1	P	p	NN
cord-334973-jemeyudi	57	2	<	<	XX
cord-334973-jemeyudi	57	3	0.05	0.05	CD
cord-334973-jemeyudi	57	4	was	be	VBD
cord-334973-jemeyudi	57	5	considered	consider	VBN
cord-334973-jemeyudi	57	6	to	to	TO
cord-334973-jemeyudi	57	7	be	be	VB
cord-334973-jemeyudi	57	8	statistically	statistically	RB
cord-334973-jemeyudi	57	9	significant	significant	JJ
cord-334973-jemeyudi	57	10	for	for	IN
cord-334973-jemeyudi	57	11	all	all	DT
cord-334973-jemeyudi	57	12	tests	test	NNS
cord-334973-jemeyudi	57	13	.	.	.
cord-334973-jemeyudi	58	1	Of	of	IN
cord-334973-jemeyudi	58	2	the	the	DT
cord-334973-jemeyudi	58	3	66	66	CD
cord-334973-jemeyudi	58	4	patients	patient	NNS
cord-334973-jemeyudi	58	5	reviewed	review	VBN
cord-334973-jemeyudi	58	6	,	,	,
cord-334973-jemeyudi	58	7	three	three	CD
cord-334973-jemeyudi	58	8	patients	patient	NNS
cord-334973-jemeyudi	58	9	were	be	VBD
cord-334973-jemeyudi	58	10	excluded	exclude	VBN
cord-334973-jemeyudi	58	11	from	from	IN
cord-334973-jemeyudi	58	12	the	the	DT
cord-334973-jemeyudi	58	13	study	study	NN
cord-334973-jemeyudi	58	14	due	due	IN
cord-334973-jemeyudi	58	15	to	to	IN
cord-334973-jemeyudi	58	16	lack	lack	NN
cord-334973-jemeyudi	58	17	of	of	IN
cord-334973-jemeyudi	58	18	data	datum	NNS
cord-334973-jemeyudi	58	19	.	.	.
cord-334973-jemeyudi	59	1	No	no	DT
cord-334973-jemeyudi	59	2	patient	patient	NN
cord-334973-jemeyudi	59	3	was	be	VBD
cord-334973-jemeyudi	59	4	excluded	exclude	VBN
cord-334973-jemeyudi	59	5	from	from	IN
cord-334973-jemeyudi	59	6	the	the	DT
cord-334973-jemeyudi	59	7	study	study	NN
cord-334973-jemeyudi	59	8	due	due	IN
cord-334973-jemeyudi	59	9	to	to	IN
cord-334973-jemeyudi	59	10	blood	blood	NN
cord-334973-jemeyudi	59	11	disease	disease	NN
cord-334973-jemeyudi	59	12	,	,	,
cord-334973-jemeyudi	59	13	AIDS	AIDS	NNP
cord-334973-jemeyudi	59	14	,	,	,
cord-334973-jemeyudi	59	15	or	or	CC
cord-334973-jemeyudi	59	16	T1DM	T1DM	NNP
cord-334973-jemeyudi	59	17	.	.	.
cord-334973-jemeyudi	60	1	Thus	thus	RB
cord-334973-jemeyudi	60	2	,	,	,
cord-334973-jemeyudi	60	3	the	the	DT
cord-334973-jemeyudi	60	4	final	final	JJ
cord-334973-jemeyudi	60	5	study	study	NN
cord-334973-jemeyudi	60	6	population	population	NN
cord-334973-jemeyudi	60	7	included	include	VBD
cord-334973-jemeyudi	60	8	63	63	CD
cord-334973-jemeyudi	60	9	people	people	NNS
cord-334973-jemeyudi	60	10	,	,	,
cord-334973-jemeyudi	60	11	of	of	IN
cord-334973-jemeyudi	60	12	whom	whom	WP
cord-334973-jemeyudi	60	13	16	16	CD
cord-334973-jemeyudi	60	14	were	be	VBD
cord-334973-jemeyudi	60	15	in	in	IN
cord-334973-jemeyudi	60	16	the	the	DT
cord-334973-jemeyudi	60	17	diabetes	diabetes	NN
cord-334973-jemeyudi	60	18	group	group	NN
cord-334973-jemeyudi	60	19	and	and	CC
cord-334973-jemeyudi	60	20	47	47	CD
cord-334973-jemeyudi	60	21	in	in	IN
cord-334973-jemeyudi	60	22	the	the	DT
cord-334973-jemeyudi	60	23	non	non	JJ
cord-334973-jemeyudi	60	24	-	-	JJ
cord-334973-jemeyudi	60	25	diabetes	diabetes	JJ
cord-334973-jemeyudi	60	26	group	group	NN
cord-334973-jemeyudi	60	27	.	.	.
cord-334973-jemeyudi	61	1	There	there	EX
cord-334973-jemeyudi	61	2	was	be	VBD
cord-334973-jemeyudi	61	3	no	no	DT
cord-334973-jemeyudi	61	4	significant	significant	JJ
cord-334973-jemeyudi	61	5	difference	difference	NN
cord-334973-jemeyudi	61	6	between	between	IN
cord-334973-jemeyudi	61	7	the	the	DT
cord-334973-jemeyudi	61	8	two	two	CD
cord-334973-jemeyudi	61	9	groups	group	NNS
cord-334973-jemeyudi	61	10	in	in	IN
cord-334973-jemeyudi	61	11	terms	term	NNS
cord-334973-jemeyudi	61	12	of	of	IN
cord-334973-jemeyudi	61	13	gender	gender	NN
cord-334973-jemeyudi	61	14	;	;	:
cord-334973-jemeyudi	61	15	age	age	NN
cord-334973-jemeyudi	61	16	;	;	:
cord-334973-jemeyudi	61	17	BMI	bmi	NN
cord-334973-jemeyudi	61	18	;	;	:
cord-334973-jemeyudi	61	19	SBP	SBP	NNP
cord-334973-jemeyudi	61	20	;	;	:
cord-334973-jemeyudi	61	21	DBP	DBP	NNP
cord-334973-jemeyudi	61	22	;	;	:
cord-334973-jemeyudi	61	23	and	and	CC
cord-334973-jemeyudi	61	24	ALT	ALT	NNP
cord-334973-jemeyudi	61	25	,	,	,
cord-334973-jemeyudi	61	26	AST	AST	NNP
cord-334973-jemeyudi	61	27	,	,	,
cord-334973-jemeyudi	61	28	and	and	CC
cord-334973-jemeyudi	61	29	Cr	cr	NN
cord-334973-jemeyudi	61	30	levels	level	NNS
cord-334973-jemeyudi	61	31	.	.	.
cord-334973-jemeyudi	62	1	There	there	EX
cord-334973-jemeyudi	62	2	was	be	VBD
cord-334973-jemeyudi	62	3	no	no	DT
cord-334973-jemeyudi	62	4	significant	significant	JJ
cord-334973-jemeyudi	62	5	difference	difference	NN
cord-334973-jemeyudi	62	6	between	between	IN
cord-334973-jemeyudi	62	7	the	the	DT
cord-334973-jemeyudi	62	8	two	two	CD
cord-334973-jemeyudi	62	9	groups	group	NNS
cord-334973-jemeyudi	62	10	in	in	IN
cord-334973-jemeyudi	62	11	maximal	maximal	JJ
cord-334973-jemeyudi	62	12	and	and	CC
cord-334973-jemeyudi	62	13	minimal	minimal	JJ
cord-334973-jemeyudi	62	14	Table	table	NN
cord-334973-jemeyudi	62	15	1	1	CD
cord-334973-jemeyudi	62	16	.	.	.
cord-334973-jemeyudi	63	1	The	the	DT
cord-334973-jemeyudi	63	2	scatter	scatter	NN
cord-334973-jemeyudi	63	3	plot	plot	NN
cord-334973-jemeyudi	63	4	shows	show	VBZ
cord-334973-jemeyudi	63	5	that	that	IN
cord-334973-jemeyudi	63	6	hospitalization	hospitalization	NN
cord-334973-jemeyudi	63	7	days	day	NNS
cord-334973-jemeyudi	63	8	(	(	-LRB-
cord-334973-jemeyudi	63	9	R	r	NN
cord-334973-jemeyudi	63	10	=	=	NN
cord-334973-jemeyudi	63	11	-0.600	-0.600	NNP
cord-334973-jemeyudi	63	12	,	,	,
cord-334973-jemeyudi	63	13	P	p	NN
cord-334973-jemeyudi	63	14	<	<	XX
cord-334973-jemeyudi	63	15	0.05	0.05	CD
cord-334973-jemeyudi	63	16	,	,	,
cord-334973-jemeyudi	63	17	Figure	figure	NN
cord-334973-jemeyudi	63	18	1	1	CD
cord-334973-jemeyudi	63	19	)	)	-RRB-
cord-334973-jemeyudi	63	20	and	and	CC
cord-334973-jemeyudi	63	21	SARS	SARS	NNP
cord-334973-jemeyudi	63	22	-	-	HYPH
cord-334973-jemeyudi	63	23	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	63	24	nucleic	nucleic	JJ
cord-334973-jemeyudi	63	25	acid	acid	NN
cord-334973-jemeyudi	63	26	positive	positive	JJ
cord-334973-jemeyudi	63	27	days	day	NNS
cord-334973-jemeyudi	63	28	(	(	-LRB-
cord-334973-jemeyudi	63	29	R	r	NN
cord-334973-jemeyudi	63	30	=	=	SYM
cord-334973-jemeyudi	63	31	-0.420	-0.420	NN
cord-334973-jemeyudi	63	32	,	,	,
cord-334973-jemeyudi	63	33	P	p	NN
cord-334973-jemeyudi	63	34	<	<	XX
cord-334973-jemeyudi	63	35	0.05	0.05	CD
cord-334973-jemeyudi	63	36	,	,	,
cord-334973-jemeyudi	63	37	Figure	figure	NN
cord-334973-jemeyudi	63	38	2	2	CD
cord-334973-jemeyudi	63	39	)	)	-RRB-
cord-334973-jemeyudi	63	40	are	be	VBP
cord-334973-jemeyudi	63	41	correlated	correlate	VBN
cord-334973-jemeyudi	63	42	with	with	IN
cord-334973-jemeyudi	63	43	minimal	minimal	JJ
cord-334973-jemeyudi	63	44	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	63	45	count	count	NN
cord-334973-jemeyudi	63	46	.	.	.
cord-334973-jemeyudi	64	1	This	this	DT
cord-334973-jemeyudi	64	2	single	single	JJ
cord-334973-jemeyudi	64	3	center	center	NN
cord-334973-jemeyudi	64	4	,	,	,
cord-334973-jemeyudi	64	5	observational	observational	JJ
cord-334973-jemeyudi	64	6	,	,	,
cord-334973-jemeyudi	64	7	retrospective	retrospective	JJ
cord-334973-jemeyudi	64	8	study	study	NN
cord-334973-jemeyudi	64	9	of	of	IN
cord-334973-jemeyudi	64	10	patients	patient	NNS
cord-334973-jemeyudi	64	11	with	with	IN
cord-334973-jemeyudi	64	12	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	64	13	showed	show	VBD
cord-334973-jemeyudi	64	14	that	that	IN
cord-334973-jemeyudi	64	15	,	,	,
cord-334973-jemeyudi	64	16	patients	patient	NNS
cord-334973-jemeyudi	64	17	with	with	IN
cord-334973-jemeyudi	64	18	T2DM	T2DM	NNP
cord-334973-jemeyudi	64	19	have	have	VBP
cord-334973-jemeyudi	64	20	higher	high	JJR
cord-334973-jemeyudi	64	21	CRP	CRP	NNP
cord-334973-jemeyudi	64	22	,	,	,
cord-334973-jemeyudi	64	23	lower	low	JJR
cord-334973-jemeyudi	64	24	level	level	NN
cord-334973-jemeyudi	64	25	and	and	CC
cord-334973-jemeyudi	64	26	more	more	RBR
cord-334973-jemeyudi	64	27	rapid	rapid	JJ
cord-334973-jemeyudi	64	28	decline	decline	NN
cord-334973-jemeyudi	64	29	in	in	IN
cord-334973-jemeyudi	64	30	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	64	31	count	count	NN
cord-334973-jemeyudi	64	32	,	,	,
cord-334973-jemeyudi	64	33	and	and	CC
cord-334973-jemeyudi	64	34	longer	long	JJR
cord-334973-jemeyudi	64	35	hospitalization	hospitalization	NN
cord-334973-jemeyudi	64	36	time	time	NN
cord-334973-jemeyudi	64	37	than	than	IN
cord-334973-jemeyudi	64	38	those	those	DT
cord-334973-jemeyudi	64	39	without	without	IN
cord-334973-jemeyudi	64	40	T2DM	T2DM	NNP
cord-334973-jemeyudi	64	41	.	.	.
cord-334973-jemeyudi	65	1	Patients	patient	NNS
cord-334973-jemeyudi	65	2	'	'	POS
cord-334973-jemeyudi	65	3	age	age	NN
cord-334973-jemeyudi	65	4	and	and	CC
cord-334973-jemeyudi	65	5	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	65	6	count	count	NN
cord-334973-jemeyudi	65	7	were	be	VBD
cord-334973-jemeyudi	65	8	negatively	negatively	RB
cord-334973-jemeyudi	65	9	correlated	correlate	VBN
cord-334973-jemeyudi	65	10	.	.	.
cord-334973-jemeyudi	66	1	Hospitalization	hospitalization	NN
cord-334973-jemeyudi	66	2	days	day	NNS
cord-334973-jemeyudi	66	3	and	and	CC
cord-334973-jemeyudi	66	4	SARS	SARS	NNP
cord-334973-jemeyudi	66	5	-	-	HYPH
cord-334973-jemeyudi	66	6	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	66	7	nucleic	nucleic	JJ
cord-334973-jemeyudi	66	8	acid	acid	NN
cord-334973-jemeyudi	66	9	positive	positive	JJ
cord-334973-jemeyudi	66	10	days	day	NNS
cord-334973-jemeyudi	66	11	were	be	VBD
cord-334973-jemeyudi	66	12	negatively	negatively	RB
cord-334973-jemeyudi	66	13	correlated	correlate	VBN
cord-334973-jemeyudi	66	14	with	with	IN
cord-334973-jemeyudi	66	15	minimal	minimal	JJ
cord-334973-jemeyudi	66	16	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	66	17	count	count	NN
cord-334973-jemeyudi	66	18	.	.	.
cord-334973-jemeyudi	67	1	Lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	67	2	are	be	VBP
cord-334973-jemeyudi	67	3	divided	divide	VBN
cord-334973-jemeyudi	67	4	into	into	IN
cord-334973-jemeyudi	67	5	T	t	NN
cord-334973-jemeyudi	67	6	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	67	7	,	,	,
cord-334973-jemeyudi	67	8	B	b	NN
cord-334973-jemeyudi	67	9	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	67	10	,	,	,
cord-334973-jemeyudi	67	11	and	and	CC
cord-334973-jemeyudi	67	12	natural	natural	JJ
cord-334973-jemeyudi	67	13	killer	killer	NN
cord-334973-jemeyudi	67	14	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	67	15	.	.	.
cord-334973-jemeyudi	68	1	When	when	WRB
cord-334973-jemeyudi	68	2	a	a	DT
cord-334973-jemeyudi	68	3	virus	virus	NN
cord-334973-jemeyudi	68	4	infects	infect	VBZ
cord-334973-jemeyudi	68	5	the	the	DT
cord-334973-jemeyudi	68	6	human	human	JJ
cord-334973-jemeyudi	68	7	body	body	NN
cord-334973-jemeyudi	68	8	,	,	,
cord-334973-jemeyudi	68	9	it	-PRON-	PRP
cord-334973-jemeyudi	68	10	binds	bind	VBZ
cord-334973-jemeyudi	68	11	to	to	IN
cord-334973-jemeyudi	68	12	the	the	DT
cord-334973-jemeyudi	68	13	receptor	receptor	NN
cord-334973-jemeyudi	68	14	,	,	,
cord-334973-jemeyudi	68	15	enters	enter	VBZ
cord-334973-jemeyudi	68	16	the	the	DT
cord-334973-jemeyudi	68	17	cell	cell	NN
cord-334973-jemeyudi	68	18	through	through	IN
cord-334973-jemeyudi	68	19	the	the	DT
cord-334973-jemeyudi	68	20	ligand	ligand	NN
cord-334973-jemeyudi	68	21	,	,	,
cord-334973-jemeyudi	68	22	replicates	replicate	VBZ
cord-334973-jemeyudi	68	23	the	the	DT
cord-334973-jemeyudi	68	24	itself	-PRON-	PRP
cord-334973-jemeyudi	68	25	,	,	,
cord-334973-jemeyudi	68	26	and	and	CC
cord-334973-jemeyudi	68	27	produces	produce	VBZ
cord-334973-jemeyudi	68	28	MHC	MHC	NNP
cord-334973-jemeyudi	68	29	-	-	HYPH
cord-334973-jemeyudi	68	30	I	-PRON-	PRP
cord-334973-jemeyudi	68	31	molecules	molecule	NNS
cord-334973-jemeyudi	68	32	and	and	CC
cord-334973-jemeyudi	68	33	MHC	MHC	NNP
cord-334973-jemeyudi	68	34	-	-	HYPH
cord-334973-jemeyudi	68	35	II	II	NNP
cord-334973-jemeyudi	68	36	molecules	molecule	NNS
cord-334973-jemeyudi	68	37	in	in	IN
cord-334973-jemeyudi	68	38	the	the	DT
cord-334973-jemeyudi	68	39	cell	cell	NN
cord-334973-jemeyudi	68	40	;	;	:
cord-334973-jemeyudi	68	41	it	-PRON-	PRP
cord-334973-jemeyudi	68	42	is	be	VBZ
cord-334973-jemeyudi	68	43	recognized	recognize	VBN
cord-334973-jemeyudi	68	44	by	by	IN
cord-334973-jemeyudi	68	45	CD4	CD4	NNP
cord-334973-jemeyudi	68	46	+	+	CC
cord-334973-jemeyudi	68	47	T	T	NNP
cord-334973-jemeyudi	68	48	cells	cell	NNS
cord-334973-jemeyudi	68	49	and	and	CC
cord-334973-jemeyudi	68	50	CD8	CD8	NNP
cord-334973-jemeyudi	68	51	+	+	CC
cord-334973-jemeyudi	68	52	T	T	NNP
cord-334973-jemeyudi	68	53	cells	cell	NNS
cord-334973-jemeyudi	68	54	after	after	IN
cord-334973-jemeyudi	68	55	presenting	present	VBG
cord-334973-jemeyudi	68	56	the	the	DT
cord-334973-jemeyudi	68	57	antigen	antigen	NN
cord-334973-jemeyudi	68	58	,	,	,
cord-334973-jemeyudi	68	59	and	and	CC
cord-334973-jemeyudi	68	60	this	this	DT
cord-334973-jemeyudi	68	61	activates	activate	VBZ
cord-334973-jemeyudi	68	62	cellular	cellular	JJ
cord-334973-jemeyudi	68	63	immunity	immunity	NN
cord-334973-jemeyudi	68	64	and	and	CC
cord-334973-jemeyudi	68	65	humoral	humoral	JJ
cord-334973-jemeyudi	68	66	immunity	immunity	NN
cord-334973-jemeyudi	68	67	,	,	,
cord-334973-jemeyudi	68	68	which	which	WDT
cord-334973-jemeyudi	68	69	help	help	VBP
cord-334973-jemeyudi	68	70	eliminate	eliminate	VB
cord-334973-jemeyudi	68	71	the	the	DT
cord-334973-jemeyudi	68	72	virus	virus	NN
cord-334973-jemeyudi	68	73	[	[	-LRB-
cord-334973-jemeyudi	68	74	6	6	CD
cord-334973-jemeyudi	68	75	,	,	,
cord-334973-jemeyudi	68	76	7	7	CD
cord-334973-jemeyudi	68	77	]	]	-RRB-
cord-334973-jemeyudi	68	78	.	.	.
cord-334973-jemeyudi	69	1	Virus	virus	NN
cord-334973-jemeyudi	69	2	clearance	clearance	NN
cord-334973-jemeyudi	69	3	depends	depend	VBZ
cord-334973-jemeyudi	69	4	on	on	IN
cord-334973-jemeyudi	69	5	the	the	DT
cord-334973-jemeyudi	69	6	body	body	NN
cord-334973-jemeyudi	69	7	's	's	POS
cord-334973-jemeyudi	69	8	normal	normal	JJ
cord-334973-jemeyudi	69	9	immune	immune	JJ
cord-334973-jemeyudi	69	10	function	function	NN
cord-334973-jemeyudi	69	11	,	,	,
cord-334973-jemeyudi	69	12	and	and	CC
cord-334973-jemeyudi	69	13	the	the	DT
cord-334973-jemeyudi	69	14	patient	patient	NN
cord-334973-jemeyudi	69	15	's	's	POS
cord-334973-jemeyudi	69	16	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	69	17	count	count	NN
cord-334973-jemeyudi	69	18	and	and	CC
cord-334973-jemeyudi	69	19	function	function	NN
cord-334973-jemeyudi	69	20	are	be	VBP
cord-334973-jemeyudi	69	21	critical	critical	JJ
cord-334973-jemeyudi	69	22	factors	factor	NNS
cord-334973-jemeyudi	69	23	.	.	.
cord-334973-jemeyudi	70	1	However	however	RB
cord-334973-jemeyudi	70	2	,	,	,
cord-334973-jemeyudi	70	3	after	after	IN
cord-334973-jemeyudi	70	4	viral	viral	JJ
cord-334973-jemeyudi	70	5	infections	infection	NNS
cord-334973-jemeyudi	70	6	,	,	,
cord-334973-jemeyudi	70	7	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	70	8	counts	count	NNS
cord-334973-jemeyudi	70	9	often	often	RB
cord-334973-jemeyudi	70	10	decline	decline	VBP
cord-334973-jemeyudi	70	11	.	.	.
cord-334973-jemeyudi	71	1	The	the	DT
cord-334973-jemeyudi	71	2	possible	possible	JJ
cord-334973-jemeyudi	71	3	causes	cause	NNS
cord-334973-jemeyudi	71	4	include	include	VBP
cord-334973-jemeyudi	71	5	the	the	DT
cord-334973-jemeyudi	71	6	consumption	consumption	NN
cord-334973-jemeyudi	71	7	of	of	IN
cord-334973-jemeyudi	71	8	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	71	9	after	after	IN
cord-334973-jemeyudi	71	10	virus	virus	NN
cord-334973-jemeyudi	71	11	invasion	invasion	NN
cord-334973-jemeyudi	71	12	,	,	,
cord-334973-jemeyudi	71	13	the	the	DT
cord-334973-jemeyudi	71	14	direct	direct	JJ
cord-334973-jemeyudi	71	15	killing	killing	NN
cord-334973-jemeyudi	71	16	of	of	IN
cord-334973-jemeyudi	71	17	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	71	18	by	by	IN
cord-334973-jemeyudi	71	19	the	the	DT
cord-334973-jemeyudi	71	20	virus	virus	NN
cord-334973-jemeyudi	71	21	,	,	,
cord-334973-jemeyudi	71	22	apoptosis	apoptosis	NN
cord-334973-jemeyudi	71	23	of	of	IN
cord-334973-jemeyudi	71	24	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	71	25	[	[	-LRB-
cord-334973-jemeyudi	71	26	8	8	CD
cord-334973-jemeyudi	71	27	]	]	-RRB-
cord-334973-jemeyudi	71	28	,	,	,
cord-334973-jemeyudi	71	29	and	and	CC
cord-334973-jemeyudi	71	30	the	the	DT
cord-334973-jemeyudi	71	31	suppression	suppression	NN
cord-334973-jemeyudi	71	32	of	of	IN
cord-334973-jemeyudi	71	33	immune	immune	JJ
cord-334973-jemeyudi	71	34	function	function	NN
cord-334973-jemeyudi	71	35	by	by	IN
cord-334973-jemeyudi	71	36	the	the	DT
cord-334973-jemeyudi	71	37	virus	virus	NN
cord-334973-jemeyudi	71	38	.	.	.
cord-334973-jemeyudi	72	1	Bo	Bo	NNP
cord-334973-jemeyudi	72	2	Diao	Diao	NNP
cord-334973-jemeyudi	72	3	et	et	FW
cord-334973-jemeyudi	72	4	al	al	NNP
cord-334973-jemeyudi	72	5	.	.	NNP
cord-334973-jemeyudi	72	6	reported	report	VBD
cord-334973-jemeyudi	72	7	a	a	DT
cord-334973-jemeyudi	72	8	decrease	decrease	NN
cord-334973-jemeyudi	72	9	in	in	IN
cord-334973-jemeyudi	72	10	T	t	NN
cord-334973-jemeyudi	72	11	-	-	HYPH
cord-334973-jemeyudi	72	12	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	72	13	count	count	NN
cord-334973-jemeyudi	72	14	in	in	IN
cord-334973-jemeyudi	72	15	patients	patient	NNS
cord-334973-jemeyudi	72	16	with	with	IN
cord-334973-jemeyudi	72	17	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	72	18	[	[	-LRB-
cord-334973-jemeyudi	72	19	9	9	CD
cord-334973-jemeyudi	72	20	]	]	-RRB-
cord-334973-jemeyudi	72	21	.	.	.
cord-334973-jemeyudi	73	1	Li	Li	NNP
cord-334973-jemeyudi	73	2	Xinmin	Xinmin	NNP
cord-334973-jemeyudi	73	3	's	's	POS
cord-334973-jemeyudi	73	4	research	research	NN
cord-334973-jemeyudi	73	5	on	on	IN
cord-334973-jemeyudi	73	6	patients	patient	NNS
cord-334973-jemeyudi	73	7	with	with	IN
cord-334973-jemeyudi	73	8	SARS	SARS	NNP
cord-334973-jemeyudi	73	9	showed	show	VBD
cord-334973-jemeyudi	73	10	that	that	IN
cord-334973-jemeyudi	73	11	the	the	DT
cord-334973-jemeyudi	73	12	absolute	absolute	JJ
cord-334973-jemeyudi	73	13	counts	count	NNS
cord-334973-jemeyudi	73	14	of	of	IN
cord-334973-jemeyudi	73	15	T	t	NN
cord-334973-jemeyudi	73	16	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	73	17	,	,	,
cord-334973-jemeyudi	73	18	T4	T4	NNP
cord-334973-jemeyudi	73	19	cells	cell	NNS
cord-334973-jemeyudi	73	20	,	,	,
cord-334973-jemeyudi	73	21	and	and	CC
cord-334973-jemeyudi	73	22	T8	t8	NN
cord-334973-jemeyudi	73	23	cells	cell	NNS
cord-334973-jemeyudi	73	24	were	be	VBD
cord-334973-jemeyudi	73	25	significantly	significantly	RB
cord-334973-jemeyudi	73	26	reduced	reduce	VBN
cord-334973-jemeyudi	73	27	,	,	,
cord-334973-jemeyudi	73	28	suggesting	suggest	VBG
cord-334973-jemeyudi	73	29	that	that	IN
cord-334973-jemeyudi	73	30	the	the	DT
cord-334973-jemeyudi	73	31	T	T	NNP
cord-334973-jemeyudi	73	32	cell	cell	NN
cord-334973-jemeyudi	73	33	immune	immune	JJ
cord-334973-jemeyudi	73	34	function	function	NN
cord-334973-jemeyudi	73	35	of	of	IN
cord-334973-jemeyudi	73	36	patients	patient	NNS
cord-334973-jemeyudi	73	37	with	with	IN
cord-334973-jemeyudi	73	38	SARS	SARS	NNP
cord-334973-jemeyudi	73	39	is	be	VBZ
cord-334973-jemeyudi	73	40	weakened	weaken	VBN
cord-334973-jemeyudi	73	41	[	[	-LRB-
cord-334973-jemeyudi	73	42	10	10	CD
cord-334973-jemeyudi	73	43	]	]	-RRB-
cord-334973-jemeyudi	73	44	.	.	.
cord-334973-jemeyudi	74	1	Liu	Liu	NNP
cord-334973-jemeyudi	74	2	et	et	NNP
cord-334973-jemeyudi	74	3	al	al	NNP
cord-334973-jemeyudi	74	4	.	.	.
cord-334973-jemeyudi	75	1	found	find	VBD
cord-334973-jemeyudi	75	2	[	[	-LRB-
cord-334973-jemeyudi	75	3	16	16	CD
cord-334973-jemeyudi	75	4	]	]	-RRB-
cord-334973-jemeyudi	75	5	counts	count	NNS
cord-334973-jemeyudi	75	6	.	.	.
cord-334973-jemeyudi	76	1	Fan	Fan	NNP
cord-334973-jemeyudi	76	2	Wang	Wang	NNP
cord-334973-jemeyudi	76	3	[	[	-LRB-
cord-334973-jemeyudi	76	4	11	11	CD
cord-334973-jemeyudi	76	5	]	]	-RRB-
cord-334973-jemeyudi	76	6	observed	observe	VBD
cord-334973-jemeyudi	76	7	that	that	IN
cord-334973-jemeyudi	76	8	patients	patient	NNS
cord-334973-jemeyudi	76	9	with	with	IN
cord-334973-jemeyudi	76	10	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	76	11	had	have	VBD
cord-334973-jemeyudi	76	12	significantly	significantly	RB
cord-334973-jemeyudi	76	13	low	low	JJ
cord-334973-jemeyudi	76	14	counts	count	NNS
cord-334973-jemeyudi	76	15	of	of	IN
cord-334973-jemeyudi	76	16	total	total	JJ
cord-334973-jemeyudi	76	17	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	76	18	(	(	-LRB-
cord-334973-jemeyudi	76	19	P	p	NN
cord-334973-jemeyudi	76	20	<	<	XX
cord-334973-jemeyudi	76	21	0.0001	0.0001	CD
cord-334973-jemeyudi	76	22	)	)	-RRB-
cord-334973-jemeyudi	76	23	,	,	,
cord-334973-jemeyudi	76	24	CD4	CD4	NNP
cord-334973-jemeyudi	76	25	+	+	CC
cord-334973-jemeyudi	76	26	T	t	NN
cord-334973-jemeyudi	76	27	cells	cell	NNS
cord-334973-jemeyudi	76	28	,	,	,
cord-334973-jemeyudi	76	29	patients	patient	NNS
cord-334973-jemeyudi	76	30	with	with	IN
cord-334973-jemeyudi	76	31	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	76	32	is	be	VBZ
cord-334973-jemeyudi	76	33	weakened	weaken	VBN
cord-334973-jemeyudi	76	34	too	too	RB
cord-334973-jemeyudi	76	35	.	.	.
cord-334973-jemeyudi	77	1	Several	several	JJ
cord-334973-jemeyudi	77	2	recent	recent	JJ
cord-334973-jemeyudi	77	3	studies	study	NNS
cord-334973-jemeyudi	77	4	have	have	VBP
cord-334973-jemeyudi	77	5	also	also	RB
cord-334973-jemeyudi	77	6	found	find	VBN
cord-334973-jemeyudi	77	7	that	that	IN
cord-334973-jemeyudi	77	8	peripheral	peripheral	JJ
cord-334973-jemeyudi	77	9	blood	blood	NN
cord-334973-jemeyudi	77	10	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	77	11	count	count	NN
cord-334973-jemeyudi	77	12	in	in	IN
cord-334973-jemeyudi	77	13	patients	patient	NNS
cord-334973-jemeyudi	77	14	with	with	IN
cord-334973-jemeyudi	77	15	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	77	16	is	be	VBZ
cord-334973-jemeyudi	77	17	reduced	reduce	VBN
cord-334973-jemeyudi	77	18	[	[	-LRB-
cord-334973-jemeyudi	77	19	4	4	CD
cord-334973-jemeyudi	77	20	,	,	,
cord-334973-jemeyudi	77	21	5	5	CD
cord-334973-jemeyudi	77	22	,	,	,
cord-334973-jemeyudi	77	23	9	9	CD
cord-334973-jemeyudi	77	24	]	]	-RRB-
cord-334973-jemeyudi	77	25	.	.	.
cord-334973-jemeyudi	78	1	Pathological	pathological	JJ
cord-334973-jemeyudi	78	2	examination	examination	NN
cord-334973-jemeyudi	78	3	of	of	IN
cord-334973-jemeyudi	78	4	the	the	DT
cord-334973-jemeyudi	78	5	spleen	spleen	NNS
cord-334973-jemeyudi	78	6	showed	show	VBD
cord-334973-jemeyudi	78	7	degeneration	degeneration	NN
cord-334973-jemeyudi	78	8	and	and	CC
cord-334973-jemeyudi	78	9	necrosis	necrosis	NN
cord-334973-jemeyudi	78	10	,	,	,
cord-334973-jemeyudi	78	11	and	and	CC
cord-334973-jemeyudi	78	12	reduction	reduction	NN
cord-334973-jemeyudi	78	13	in	in	IN
cord-334973-jemeyudi	78	14	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	78	15	[	[	-LRB-
cord-334973-jemeyudi	78	16	12	12	CD
cord-334973-jemeyudi	78	17	]	]	-RRB-
cord-334973-jemeyudi	78	18	,	,	,
cord-334973-jemeyudi	78	19	which	which	WDT
cord-334973-jemeyudi	78	20	indirectly	indirectly	RB
cord-334973-jemeyudi	78	21	reflected	reflect	VBD
cord-334973-jemeyudi	78	22	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	78	23	depletion	depletion	NN
cord-334973-jemeyudi	78	24	or	or	CC
cord-334973-jemeyudi	78	25	immunosuppression	immunosuppression	NN
cord-334973-jemeyudi	78	26	.	.	.
cord-334973-jemeyudi	79	1	Our	-PRON-	PRP$
cord-334973-jemeyudi	79	2	study	study	NN
cord-334973-jemeyudi	79	3	found	find	VBD
cord-334973-jemeyudi	79	4	a	a	DT
cord-334973-jemeyudi	79	5	decrease	decrease	NN
cord-334973-jemeyudi	79	6	in	in	IN
cord-334973-jemeyudi	79	7	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	79	8	count	count	NN
cord-334973-jemeyudi	79	9	in	in	IN
cord-334973-jemeyudi	79	10	patients	patient	NNS
cord-334973-jemeyudi	79	11	with	with	IN
cord-334973-jemeyudi	79	12	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	79	13	,	,	,
cord-334973-jemeyudi	79	14	and	and	CC
cord-334973-jemeyudi	79	15	the	the	DT
cord-334973-jemeyudi	79	16	lower	low	JJR
cord-334973-jemeyudi	79	17	the	the	DT
cord-334973-jemeyudi	79	18	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	79	19	count	count	NN
cord-334973-jemeyudi	79	20	,	,	,
cord-334973-jemeyudi	79	21	the	the	DT
cord-334973-jemeyudi	79	22	longer	long	JJR
cord-334973-jemeyudi	79	23	SARS	SARS	NNP
cord-334973-jemeyudi	79	24	-	-	HYPH
cord-334973-jemeyudi	79	25	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	79	26	nucleic	nucleic	JJ
cord-334973-jemeyudi	79	27	acid	acid	NN
cord-334973-jemeyudi	79	28	positive	positive	JJ
cord-334973-jemeyudi	79	29	days	day	NNS
cord-334973-jemeyudi	79	30	and	and	CC
cord-334973-jemeyudi	79	31	hospitalization	hospitalization	NN
cord-334973-jemeyudi	79	32	days	day	NNS
cord-334973-jemeyudi	79	33	.	.	.
cord-334973-jemeyudi	80	1	It	-PRON-	PRP
cord-334973-jemeyudi	80	2	is	be	VBZ
cord-334973-jemeyudi	80	3	suggested	suggest	VBN
cord-334973-jemeyudi	80	4	that	that	IN
cord-334973-jemeyudi	80	5	the	the	DT
cord-334973-jemeyudi	80	6	decrease	decrease	NN
cord-334973-jemeyudi	80	7	in	in	IN
cord-334973-jemeyudi	80	8	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	80	9	is	be	VBZ
cord-334973-jemeyudi	80	10	one	one	CD
cord-334973-jemeyudi	80	11	of	of	IN
cord-334973-jemeyudi	80	12	the	the	DT
cord-334973-jemeyudi	80	13	characteristics	characteristic	NNS
cord-334973-jemeyudi	80	14	of	of	IN
cord-334973-jemeyudi	80	15	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	80	16	,	,	,
cord-334973-jemeyudi	80	17	and	and	CC
cord-334973-jemeyudi	80	18	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	80	19	play	play	VBP
cord-334973-jemeyudi	80	20	an	an	DT
cord-334973-jemeyudi	80	21	important	important	JJ
cord-334973-jemeyudi	80	22	role	role	NN
cord-334973-jemeyudi	80	23	in	in	IN
cord-334973-jemeyudi	80	24	the	the	DT
cord-334973-jemeyudi	80	25	virus	virus	NN
cord-334973-jemeyudi	80	26	clearance	clearance	NN
cord-334973-jemeyudi	80	27	in	in	IN
cord-334973-jemeyudi	80	28	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	80	29	patients	patient	NNS
cord-334973-jemeyudi	80	30	.	.	.
cord-334973-jemeyudi	81	1	A	a	DT
cord-334973-jemeyudi	81	2	meta	meta	JJ
cord-334973-jemeyudi	81	3	-	-	HYPH
cord-334973-jemeyudi	81	4	analysis	analysis	NN
cord-334973-jemeyudi	81	5	[	[	-LRB-
cord-334973-jemeyudi	81	6	13	13	CD
cord-334973-jemeyudi	81	7	]	]	-RRB-
cord-334973-jemeyudi	81	8	showed	show	VBD
cord-334973-jemeyudi	81	9	that	that	IN
cord-334973-jemeyudi	81	10	lymphopenia	lymphopenia	NNP
cord-334973-jemeyudi	81	11	on	on	IN
cord-334973-jemeyudi	81	12	admission	admission	NN
cord-334973-jemeyudi	81	13	was	be	VBD
cord-334973-jemeyudi	81	14	associated	associate	VBN
cord-334973-jemeyudi	81	15	with	with	IN
cord-334973-jemeyudi	81	16	poor	poor	JJ
cord-334973-jemeyudi	81	17	outcomes	outcome	NNS
cord-334973-jemeyudi	81	18	in	in	IN
cord-334973-jemeyudi	81	19	patients	patient	NNS
cord-334973-jemeyudi	81	20	with	with	IN
cord-334973-jemeyudi	81	21	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	81	22	.	.	.
cord-334973-jemeyudi	82	1	According	accord	VBG
cord-334973-jemeyudi	82	2	to	to	IN
cord-334973-jemeyudi	82	3	some	some	DT
cord-334973-jemeyudi	82	4	studies	study	NNS
cord-334973-jemeyudi	82	5	[	[	-LRB-
cord-334973-jemeyudi	82	6	14	14	CD
cord-334973-jemeyudi	82	7	]	]	-RRB-
cord-334973-jemeyudi	82	8	[	[	-LRB-
cord-334973-jemeyudi	82	9	8	8	CD
cord-334973-jemeyudi	82	10	,	,	,
cord-334973-jemeyudi	82	11	15	15	CD
cord-334973-jemeyudi	82	12	]	]	-RRB-
cord-334973-jemeyudi	82	13	,	,	,
cord-334973-jemeyudi	82	14	decreased	decrease	VBD
cord-334973-jemeyudi	82	15	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	82	16	count	count	NN
cord-334973-jemeyudi	82	17	is	be	VBZ
cord-334973-jemeyudi	82	18	a	a	DT
cord-334973-jemeyudi	82	19	characteristic	characteristic	NN
cord-334973-jemeyudi	82	20	of	of	IN
cord-334973-jemeyudi	82	21	severe	severe	JJ
cord-334973-jemeyudi	82	22	COVID-19	covid-19	NN
cord-334973-jemeyudi	82	23	.	.	.
cord-334973-jemeyudi	83	1	Among	among	IN
cord-334973-jemeyudi	83	2	the	the	DT
cord-334973-jemeyudi	83	3	patients	patient	NNS
cord-334973-jemeyudi	83	4	enrolled	enrol	VBN
cord-334973-jemeyudi	83	5	,	,	,
cord-334973-jemeyudi	83	6	the	the	DT
cord-334973-jemeyudi	83	7	median	median	JJ
cord-334973-jemeyudi	83	8	time	time	NN
cord-334973-jemeyudi	83	9	of	of	IN
cord-334973-jemeyudi	83	10	onset	onset	NN
cord-334973-jemeyudi	83	11	to	to	IN
cord-334973-jemeyudi	83	12	RT	RT	NNP
cord-334973-jemeyudi	83	13	-	-	HYPH
cord-334973-jemeyudi	83	14	PCR	PCR	NNP
cord-334973-jemeyudi	83	15	turning	turn	VBG
cord-334973-jemeyudi	83	16	negative	negative	JJ
cord-334973-jemeyudi	83	17	was	be	VBD
cord-334973-jemeyudi	83	18	14	14	CD
cord-334973-jemeyudi	83	19	(	(	-LRB-
cord-334973-jemeyudi	83	20	IQR	IQR	NNP
cord-334973-jemeyudi	83	21	,	,	,
cord-334973-jemeyudi	83	22	[	[	-LRB-
cord-334973-jemeyudi	83	23	10	10	CD
cord-334973-jemeyudi	83	24	]	]	-RRB-
cord-334973-jemeyudi	83	25	[	[	-LRB-
cord-334973-jemeyudi	83	26	11	11	CD
cord-334973-jemeyudi	83	27	]	]	-RRB-
cord-334973-jemeyudi	83	28	[	[	-LRB-
cord-334973-jemeyudi	83	29	12	12	CD
cord-334973-jemeyudi	83	30	]	]	-RRB-
cord-334973-jemeyudi	83	31	[	[	-LRB-
cord-334973-jemeyudi	83	32	13	13	CD
cord-334973-jemeyudi	83	33	]	]	-RRB-
cord-334973-jemeyudi	84	1	[	[	-LRB-
cord-334973-jemeyudi	84	2	14	14	CD
cord-334973-jemeyudi	84	3	]	]	-RRB-
cord-334973-jemeyudi	85	1	[	[	-LRB-
cord-334973-jemeyudi	85	2	15	15	CD
cord-334973-jemeyudi	85	3	]	]	-RRB-
cord-334973-jemeyudi	85	4	[	[	-LRB-
cord-334973-jemeyudi	85	5	16	16	CD
cord-334973-jemeyudi	85	6	]	]	-RRB-
cord-334973-jemeyudi	85	7	[	[	-LRB-
cord-334973-jemeyudi	85	8	17	17	CD
cord-334973-jemeyudi	85	9	]	]	-RRB-
cord-334973-jemeyudi	85	10	[	[	-LRB-
cord-334973-jemeyudi	85	11	18	18	CD
cord-334973-jemeyudi	85	12	]	]	-RRB-
cord-334973-jemeyudi	85	13	[	[	-LRB-
cord-334973-jemeyudi	85	14	19	19	CD
cord-334973-jemeyudi	85	15	]	]	-RRB-
cord-334973-jemeyudi	85	16	[	[	-LRB-
cord-334973-jemeyudi	85	17	20	20	CD
cord-334973-jemeyudi	85	18	]	]	-RRB-
cord-334973-jemeyudi	85	19	days	day	NNS
cord-334973-jemeyudi	85	20	.	.	.
cord-334973-jemeyudi	86	1	In	in	IN
cord-334973-jemeyudi	86	2	groups	group	NNS
cord-334973-jemeyudi	86	3	with	with	IN
cord-334973-jemeyudi	86	4	rapid	rapid	JJ
cord-334973-jemeyudi	86	5	virus	virus	NN
cord-334973-jemeyudi	86	6	clearance	clearance	NN
cord-334973-jemeyudi	86	7	,	,	,
cord-334973-jemeyudi	86	8	high	high	JJ
cord-334973-jemeyudi	86	9	counts	count	NNS
cord-334973-jemeyudi	86	10	of	of	IN
cord-334973-jemeyudi	86	11	T	t	NN
cord-334973-jemeyudi	86	12	cells	cell	NNS
cord-334973-jemeyudi	86	13	,	,	,
cord-334973-jemeyudi	86	14	CD4	CD4	NNP
cord-334973-jemeyudi	86	15	+	+	CC
cord-334973-jemeyudi	86	16	T	t	NN
cord-334973-jemeyudi	86	17	cells	cell	NNS
cord-334973-jemeyudi	86	18	,	,	,
cord-334973-jemeyudi	86	19	CD8	CD8	NNP
cord-334973-jemeyudi	86	20	+	+	CC
cord-334973-jemeyudi	86	21	T	T	NNP
cord-334973-jemeyudi	86	22	cells	cell	NNS
cord-334973-jemeyudi	86	23	,	,	,
cord-334973-jemeyudi	86	24	and	and	CC
cord-334973-jemeyudi	86	25	B	b	NN
cord-334973-jemeyudi	86	26	cells	cell	NNS
cord-334973-jemeyudi	86	27	were	be	VBD
cord-334973-jemeyudi	86	28	observed	observe	VBN
cord-334973-jemeyudi	86	29	.	.	.
cord-334973-jemeyudi	87	1	In	in	IN
cord-334973-jemeyudi	87	2	our	-PRON-	PRP$
cord-334973-jemeyudi	87	3	study	study	NN
cord-334973-jemeyudi	87	4	,	,	,
cord-334973-jemeyudi	87	5	we	-PRON-	PRP
cord-334973-jemeyudi	87	6	found	find	VBD
cord-334973-jemeyudi	87	7	that	that	IN
cord-334973-jemeyudi	87	8	SARS	SARS	NNP
cord-334973-jemeyudi	87	9	-	-	HYPH
cord-334973-jemeyudi	87	10	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	87	11	nucleic	nucleic	JJ
cord-334973-jemeyudi	87	12	acid	acid	NN
cord-334973-jemeyudi	87	13	positive	positive	JJ
cord-334973-jemeyudi	87	14	days	day	NNS
cord-334973-jemeyudi	87	15	were	be	VBD
cord-334973-jemeyudi	87	16	negative	negative	JJ
cord-334973-jemeyudi	87	17	correlated	correlate	VBN
cord-334973-jemeyudi	87	18	with	with	IN
cord-334973-jemeyudi	87	19	the	the	DT
cord-334973-jemeyudi	87	20	minimal	minimal	JJ
cord-334973-jemeyudi	87	21	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	87	22	count	count	NN
cord-334973-jemeyudi	87	23	.	.	.
cord-334973-jemeyudi	88	1	Patients	patient	NNS
cord-334973-jemeyudi	88	2	with	with	IN
cord-334973-jemeyudi	88	3	T2DM	T2DM	NNP
cord-334973-jemeyudi	88	4	often	often	RB
cord-334973-jemeyudi	88	5	experience	experience	VBP
cord-334973-jemeyudi	88	6	immune	immune	JJ
cord-334973-jemeyudi	88	7	impairment	impairment	NN
cord-334973-jemeyudi	88	8	.	.	.
cord-334973-jemeyudi	89	1	Bailin	Bailin	NNP
cord-334973-jemeyudi	89	2	et	et	NNP
cord-334973-jemeyudi	89	3	al	al	NNP
cord-334973-jemeyudi	89	4	.	.	.
cord-334973-jemeyudi	90	1	found	find	VBD
cord-334973-jemeyudi	90	2	that	that	IN
cord-334973-jemeyudi	90	3	CD4	CD4	NNP
cord-334973-jemeyudi	90	4	+	+	CC
cord-334973-jemeyudi	90	5	and	and	CC
cord-334973-jemeyudi	90	6	CD8	CD8	NNP
cord-334973-jemeyudi	90	7	+	+	CC
cord-334973-jemeyudi	90	8	T	T	NNP
cord-334973-jemeyudi	90	9	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	90	10	counts	count	NNS
cord-334973-jemeyudi	90	11	are	be	VBP
cord-334973-jemeyudi	90	12	lower	low	JJR
cord-334973-jemeyudi	90	13	in	in	IN
cord-334973-jemeyudi	90	14	diabetic	diabetic	JJ
cord-334973-jemeyudi	90	15	patients	patient	NNS
cord-334973-jemeyudi	90	16	than	than	IN
cord-334973-jemeyudi	90	17	in	in	IN
cord-334973-jemeyudi	90	18	non	non	JJ
cord-334973-jemeyudi	90	19	-	-	JJ
cord-334973-jemeyudi	90	20	diabetic	diabetic	JJ
cord-334973-jemeyudi	90	21	patients	patient	NNS
cord-334973-jemeyudi	90	22	[	[	-LRB-
cord-334973-jemeyudi	90	23	17	17	CD
cord-334973-jemeyudi	90	24	]	]	-RRB-
cord-334973-jemeyudi	90	25	.	.	.
cord-334973-jemeyudi	91	1	According	accord	VBG
cord-334973-jemeyudi	91	2	to	to	IN
cord-334973-jemeyudi	91	3	a	a	DT
cord-334973-jemeyudi	91	4	Japanese	japanese	JJ
cord-334973-jemeyudi	91	5	research	research	NN
cord-334973-jemeyudi	91	6	[	[	-LRB-
cord-334973-jemeyudi	91	7	18	18	CD
cord-334973-jemeyudi	91	8	]	]	-RRB-
cord-334973-jemeyudi	91	9	,	,	,
cord-334973-jemeyudi	91	10	CD3+CD56	CD3+CD56	NNP
cord-334973-jemeyudi	91	11	+	+	CC
cord-334973-jemeyudi	91	12	T	T	NNP
cord-334973-jemeyudi	91	13	cell%	cell%	NN
cord-334973-jemeyudi	91	14	(	(	-LRB-
cord-334973-jemeyudi	91	15	4.1	4.1	CD
cord-334973-jemeyudi	91	16	+	+	SYM
cord-334973-jemeyudi	91	17	/-1.9	/-1.9	CD
cord-334973-jemeyudi	91	18	%	%	NN
cord-334973-jemeyudi	91	19	)	)	-RRB-
cord-334973-jemeyudi	91	20	of	of	IN
cord-334973-jemeyudi	91	21	patients	patient	NNS
cord-334973-jemeyudi	91	22	with	with	IN
cord-334973-jemeyudi	91	23	pancreatic	pancreatic	NN
cord-334973-jemeyudi	91	24	DM	dm	NN
cord-334973-jemeyudi	91	25	was	be	VBD
cord-334973-jemeyudi	91	26	lower	low	JJR
cord-334973-jemeyudi	91	27	than	than	IN
cord-334973-jemeyudi	91	28	that	that	DT
cord-334973-jemeyudi	91	29	(	(	-LRB-
cord-334973-jemeyudi	91	30	6.0	6.0	CD
cord-334973-jemeyudi	91	31	+	+	CC
cord-334973-jemeyudi	91	32	/-3.0	/-3.0	CD
cord-334973-jemeyudi	91	33	%	%	NN
cord-334973-jemeyudi	91	34	)	)	-RRB-
cord-334973-jemeyudi	91	35	of	of	IN
cord-334973-jemeyudi	91	36	normal	normal	JJ
cord-334973-jemeyudi	91	37	subjects	subject	NNS
cord-334973-jemeyudi	91	38	(	(	-LRB-
cord-334973-jemeyudi	91	39	p	p	NN
cord-334973-jemeyudi	91	40	<	<	XX
cord-334973-jemeyudi	91	41	0.05	0.05	CD
cord-334973-jemeyudi	91	42	)	)	-RRB-
cord-334973-jemeyudi	91	43	.	.	.
cord-334973-jemeyudi	92	1	CD3+CD56	CD3+CD56	NNP
cord-334973-jemeyudi	92	2	+	+	CC
cord-334973-jemeyudi	92	3	T	t	NN
cord-334973-jemeyudi	92	4	cells	cell	NNS
cord-334973-jemeyudi	92	5	have	have	VBP
cord-334973-jemeyudi	92	6	cytotoxic	cytotoxic	JJ
cord-334973-jemeyudi	92	7	activity	activity	NN
cord-334973-jemeyudi	92	8	and	and	CC
cord-334973-jemeyudi	92	9	it	-PRON-	PRP
cord-334973-jemeyudi	92	10	is	be	VBZ
cord-334973-jemeyudi	92	11	likely	likely	JJ
cord-334973-jemeyudi	92	12	that	that	IN
cord-334973-jemeyudi	92	13	this	this	DT
cord-334973-jemeyudi	92	14	activity	activity	NN
cord-334973-jemeyudi	92	15	is	be	VBZ
cord-334973-jemeyudi	92	16	similar	similar	JJ
cord-334973-jemeyudi	92	17	to	to	IN
cord-334973-jemeyudi	92	18	that	that	DT
cord-334973-jemeyudi	92	19	of	of	IN
cord-334973-jemeyudi	92	20	NK	NK	NNP
cord-334973-jemeyudi	92	21	cells	cell	NNS
cord-334973-jemeyudi	92	22	.	.	.
cord-334973-jemeyudi	93	1	These	these	DT
cord-334973-jemeyudi	93	2	results	result	NNS
cord-334973-jemeyudi	93	3	suggest	suggest	VBP
cord-334973-jemeyudi	93	4	that	that	IN
cord-334973-jemeyudi	93	5	a	a	DT
cord-334973-jemeyudi	93	6	decrease	decrease	NN
cord-334973-jemeyudi	93	7	in	in	IN
cord-334973-jemeyudi	93	8	peripheral	peripheral	JJ
cord-334973-jemeyudi	93	9	CD3+CD56	CD3+CD56	NNP
cord-334973-jemeyudi	93	10	+	+	CC
cord-334973-jemeyudi	93	11	T	T	NNP
cord-334973-jemeyudi	93	12	cell%	cell%	NN
cord-334973-jemeyudi	93	13	is	be	VBZ
cord-334973-jemeyudi	93	14	a	a	DT
cord-334973-jemeyudi	93	15	factor	factor	NN
cord-334973-jemeyudi	93	16	reflecting	reflect	VBG
cord-334973-jemeyudi	93	17	weak	weak	JJ
cord-334973-jemeyudi	93	18	host	host	NN
cord-334973-jemeyudi	93	19	defense	defense	NN
cord-334973-jemeyudi	93	20	to	to	IN
cord-334973-jemeyudi	93	21	infectious	infectious	JJ
cord-334973-jemeyudi	93	22	diseases	disease	NNS
cord-334973-jemeyudi	93	23	in	in	IN
cord-334973-jemeyudi	93	24	cases	case	NNS
cord-334973-jemeyudi	93	25	of	of	IN
cord-334973-jemeyudi	93	26	pancreatic	pancreatic	NN
cord-334973-jemeyudi	93	27	DM	dm	NN
cord-334973-jemeyudi	93	28	.	.	.
cord-334973-jemeyudi	94	1	The	the	DT
cord-334973-jemeyudi	94	2	SARS	SARS	NNP
cord-334973-jemeyudi	94	3	-	-	HYPH
cord-334973-jemeyudi	94	4	CoV-2	CoV-2	NNP
cord-334973-jemeyudi	94	5	merges	merge	VBZ
cord-334973-jemeyudi	94	6	with	with	IN
cord-334973-jemeyudi	94	7	target	target	NN
cord-334973-jemeyudi	94	8	cells	cell	NNS
cord-334973-jemeyudi	94	9	with	with	IN
cord-334973-jemeyudi	94	10	the	the	DT
cord-334973-jemeyudi	94	11	help	help	NN
cord-334973-jemeyudi	94	12	of	of	IN
cord-334973-jemeyudi	94	13	angiotensin	angiotensin	NN
cord-334973-jemeyudi	94	14	converting	convert	VBG
cord-334973-jemeyudi	94	15	enzyme	enzyme	NN
cord-334973-jemeyudi	94	16	2	2	CD
cord-334973-jemeyudi	94	17	(	(	-LRB-
cord-334973-jemeyudi	94	18	ACE2	ACE2	NNP
cord-334973-jemeyudi	94	19	)	)	-RRB-
cord-334973-jemeyudi	94	20	,	,	,
cord-334973-jemeyudi	94	21	which	which	WDT
cord-334973-jemeyudi	94	22	is	be	VBZ
cord-334973-jemeyudi	94	23	expressed	express	VBN
cord-334973-jemeyudi	94	24	by	by	IN
cord-334973-jemeyudi	94	25	epithelial	epithelial	JJ
cord-334973-jemeyudi	94	26	cells	cell	NNS
cord-334973-jemeyudi	94	27	of	of	IN
cord-334973-jemeyudi	94	28	the	the	DT
cord-334973-jemeyudi	94	29	lung	lung	NN
cord-334973-jemeyudi	94	30	,	,	,
cord-334973-jemeyudi	94	31	intestine	intestine	NN
cord-334973-jemeyudi	94	32	,	,	,
cord-334973-jemeyudi	94	33	and	and	CC
cord-334973-jemeyudi	94	34	kidney	kidney	NN
cord-334973-jemeyudi	94	35	[	[	-LRB-
cord-334973-jemeyudi	94	36	19	19	CD
cord-334973-jemeyudi	94	37	]	]	-RRB-
cord-334973-jemeyudi	94	38	.	.	.
cord-334973-jemeyudi	95	1	Studies	study	NNS
cord-334973-jemeyudi	95	2	have	have	VBP
cord-334973-jemeyudi	95	3	shown	show	VBN
cord-334973-jemeyudi	95	4	that	that	IN
cord-334973-jemeyudi	95	5	the	the	DT
cord-334973-jemeyudi	95	6	expression	expression	NN
cord-334973-jemeyudi	95	7	of	of	IN
cord-334973-jemeyudi	95	8	ACE2	ACE2	NNP
cord-334973-jemeyudi	95	9	in	in	IN
cord-334973-jemeyudi	95	10	diabetic	diabetic	JJ
cord-334973-jemeyudi	95	11	patients	patient	NNS
cord-334973-jemeyudi	95	12	is	be	VBZ
cord-334973-jemeyudi	95	13	significantly	significantly	RB
cord-334973-jemeyudi	95	14	increased	increase	VBN
cord-334973-jemeyudi	95	15	,	,	,
cord-334973-jemeyudi	95	16	and	and	CC
cord-334973-jemeyudi	95	17	it	-PRON-	PRP
cord-334973-jemeyudi	95	18	seems	seem	VBZ
cord-334973-jemeyudi	95	19	that	that	IN
cord-334973-jemeyudi	95	20	they	-PRON-	PRP
cord-334973-jemeyudi	95	21	are	be	VBP
cord-334973-jemeyudi	95	22	more	more	RBR
cord-334973-jemeyudi	95	23	likely	likely	JJ
cord-334973-jemeyudi	95	24	to	to	TO
cord-334973-jemeyudi	95	25	be	be	VB
cord-334973-jemeyudi	95	26	infected	infect	VBN
cord-334973-jemeyudi	95	27	with	with	IN
cord-334973-jemeyudi	95	28	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	95	29	[	[	-LRB-
cord-334973-jemeyudi	95	30	20	20	CD
cord-334973-jemeyudi	95	31	]	]	-RRB-
cord-334973-jemeyudi	95	32	.	.	.
cord-334973-jemeyudi	96	1	Yoshikawa	Yoshikawa	NNP
cord-334973-jemeyudi	96	2	et	et	NNP
cord-334973-jemeyudi	96	3	al	al	NNP
cord-334973-jemeyudi	96	4	.	.	.
cord-334973-jemeyudi	97	1	found	find	VBN
cord-334973-jemeyudi	97	2	through	through	IN
cord-334973-jemeyudi	97	3	animal	animal	NN
cord-334973-jemeyudi	97	4	experiments	experiment	NNS
cord-334973-jemeyudi	97	5	that	that	WDT
cord-334973-jemeyudi	97	6	the	the	DT
cord-334973-jemeyudi	97	7	overexpression	overexpression	NN
cord-334973-jemeyudi	97	8	of	of	IN
cord-334973-jemeyudi	97	9	ACE2	ACE2	NNP
cord-334973-jemeyudi	97	10	reduces	reduce	VBZ
cord-334973-jemeyudi	97	11	the	the	DT
cord-334973-jemeyudi	97	12	activity	activity	NN
cord-334973-jemeyudi	97	13	of	of	IN
cord-334973-jemeyudi	97	14	the	the	DT
cord-334973-jemeyudi	97	15	T	t	NN
cord-334973-jemeyudi	97	16	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	97	17	against	against	IN
cord-334973-jemeyudi	97	18	SARS	SARS	NNP
cord-334973-jemeyudi	97	19	-	-	HYPH
cord-334973-jemeyudi	97	20	CoV	CoV	NNP
cord-334973-jemeyudi	97	21	and	and	CC
cord-334973-jemeyudi	97	22	impairs	impair	VBZ
cord-334973-jemeyudi	97	23	the	the	DT
cord-334973-jemeyudi	97	24	immune	immune	JJ
cord-334973-jemeyudi	97	25	function	function	NN
cord-334973-jemeyudi	97	26	[	[	-LRB-
cord-334973-jemeyudi	97	27	21	21	CD
cord-334973-jemeyudi	97	28	]	]	-RRB-
cord-334973-jemeyudi	97	29	.	.	.
cord-334973-jemeyudi	98	1	Gupta	Gupta	NNP
cord-334973-jemeyudi	98	2	et	et	NNP
cord-334973-jemeyudi	98	3	al	al	NNP
cord-334973-jemeyudi	98	4	.	.	.
cord-334973-jemeyudi	99	1	found	find	VBD
cord-334973-jemeyudi	99	2	that	that	IN
cord-334973-jemeyudi	99	3	diabetes	diabetes	NN
cord-334973-jemeyudi	99	4	enhances	enhance	VBZ
cord-334973-jemeyudi	99	5	the	the	DT
cord-334973-jemeyudi	99	6	severity	severity	NN
cord-334973-jemeyudi	99	7	of	of	IN
cord-334973-jemeyudi	99	8	COVID-19	covid-19	JJ
cord-334973-jemeyudi	99	9	and	and	CC
cord-334973-jemeyudi	99	10	several	several	JJ
cord-334973-jemeyudi	99	11	factors	factor	NNS
cord-334973-jemeyudi	99	12	may	may	MD
cord-334973-jemeyudi	99	13	be	be	VB
cord-334973-jemeyudi	99	14	responsible	responsible	JJ
cord-334973-jemeyudi	99	15	for	for	IN
cord-334973-jemeyudi	99	16	this	this	DT
cord-334973-jemeyudi	99	17	[	[	-LRB-
cord-334973-jemeyudi	99	18	22	22	CD
cord-334973-jemeyudi	99	19	]	]	-RRB-
cord-334973-jemeyudi	99	20	:	:	:
cord-334973-jemeyudi	99	21	(	(	-LRB-
cord-334973-jemeyudi	99	22	1	1	LS
cord-334973-jemeyudi	99	23	)	)	-RRB-
cord-334973-jemeyudi	99	24	Hyperglycemia	hyperglycemia	NN
cord-334973-jemeyudi	99	25	and	and	CC
cord-334973-jemeyudi	99	26	possibly	possibly	RB
cord-334973-jemeyudi	99	27	hypoglycemia	hypoglycemia	NN
cord-334973-jemeyudi	99	28	;	;	:
cord-334973-jemeyudi	99	29	(	(	-LRB-
cord-334973-jemeyudi	99	30	2	2	LS
cord-334973-jemeyudi	99	31	)	)	-RRB-
cord-334973-jemeyudi	99	32	immune	immune	JJ
cord-334973-jemeyudi	99	33	defects	defect	NNS
cord-334973-jemeyudi	99	34	especially	especially	RB
cord-334973-jemeyudi	99	35	impaired	impair	VBD
cord-334973-jemeyudi	99	36	T	t	NN
cord-334973-jemeyudi	99	37	-	-	HYPH
cord-334973-jemeyudi	99	38	cell	cell	NN
cord-334973-jemeyudi	99	39	response	response	NN
cord-334973-jemeyudi	99	40	;	;	:
cord-334973-jemeyudi	99	41	and	and	CC
cord-334973-jemeyudi	99	42	(	(	-LRB-
cord-334973-jemeyudi	99	43	3	3	LS
cord-334973-jemeyudi	99	44	)	)	-RRB-
cord-334973-jemeyudi	99	45	associated	associate	VBD
cord-334973-jemeyudi	99	46	comorbidities	comorbiditie	NNS
cord-334973-jemeyudi	99	47	like	like	IN
cord-334973-jemeyudi	99	48	obesity	obesity	NN
cord-334973-jemeyudi	99	49	,	,	,
cord-334973-jemeyudi	99	50	heart	heart	NN
cord-334973-jemeyudi	99	51	diseases	disease	NNS
cord-334973-jemeyudi	99	52	,	,	,
cord-334973-jemeyudi	99	53	and	and	CC
cord-334973-jemeyudi	99	54	kidney	kidney	NN
cord-334973-jemeyudi	99	55	diseases	disease	NNS
cord-334973-jemeyudi	99	56	.	.	.
cord-334973-jemeyudi	100	1	According	accord	VBG
cord-334973-jemeyudi	100	2	to	to	IN
cord-334973-jemeyudi	100	3	Muniyappa	Muniyappa	NNP
cord-334973-jemeyudi	100	4	et	et	NNP
cord-334973-jemeyudi	100	5	al	al	NNP
cord-334973-jemeyudi	100	6	.	.	NNP
cord-334973-jemeyudi	100	7	,	,	,
cord-334973-jemeyudi	100	8	diminished	diminish	VBD
cord-334973-jemeyudi	100	9	T	T	NNP
cord-334973-jemeyudi	100	10	cell	cell	NN
cord-334973-jemeyudi	100	11	function	function	NN
cord-334973-jemeyudi	100	12	could	could	MD
cord-334973-jemeyudi	100	13	be	be	VB
cord-334973-jemeyudi	100	14	one	one	CD
cord-334973-jemeyudi	100	15	of	of	IN
cord-334973-jemeyudi	100	16	the	the	DT
cord-334973-jemeyudi	100	17	reasons	reason	NNS
cord-334973-jemeyudi	100	18	[	[	-LRB-
cord-334973-jemeyudi	100	19	8	8	CD
cord-334973-jemeyudi	100	20	]	]	-RRB-
cord-334973-jemeyudi	100	21	.	.	.
cord-334973-jemeyudi	101	1	In	in	IN
cord-334973-jemeyudi	101	2	our	-PRON-	PRP$
cord-334973-jemeyudi	101	3	study	study	NN
cord-334973-jemeyudi	101	4	,	,	,
cord-334973-jemeyudi	101	5	we	-PRON-	PRP
cord-334973-jemeyudi	101	6	found	find	VBD
cord-334973-jemeyudi	101	7	that	that	IN
cord-334973-jemeyudi	101	8	diabetic	diabetic	JJ
cord-334973-jemeyudi	101	9	patients	patient	NNS
cord-334973-jemeyudi	101	10	showed	show	VBD
cord-334973-jemeyudi	101	11	a	a	DT
cord-334973-jemeyudi	101	12	faster	fast	JJR
cord-334973-jemeyudi	101	13	decline	decline	NN
cord-334973-jemeyudi	101	14	in	in	IN
cord-334973-jemeyudi	101	15	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	101	16	count	count	NN
cord-334973-jemeyudi	101	17	,	,	,
cord-334973-jemeyudi	101	18	lower	lower	VB
cord-334973-jemeyudi	101	19	minimal	minimal	JJ
cord-334973-jemeyudi	101	20	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	101	21	count	count	NN
cord-334973-jemeyudi	101	22	,	,	,
cord-334973-jemeyudi	101	23	higher	high	JJR
cord-334973-jemeyudi	101	24	maximal	maximal	JJ
cord-334973-jemeyudi	101	25	CRP	crp	NN
cord-334973-jemeyudi	101	26	,	,	,
cord-334973-jemeyudi	101	27	and	and	CC
cord-334973-jemeyudi	101	28	longer	long	JJR
cord-334973-jemeyudi	101	29	hospital	hospital	NN
cord-334973-jemeyudi	101	30	stay	stay	NN
cord-334973-jemeyudi	101	31	than	than	IN
cord-334973-jemeyudi	101	32	non	non	JJ
cord-334973-jemeyudi	101	33	-	-	JJ
cord-334973-jemeyudi	101	34	diabetic	diabetic	JJ
cord-334973-jemeyudi	101	35	patients	patient	NNS
cord-334973-jemeyudi	101	36	.	.	.
cord-334973-jemeyudi	102	1	Although	although	IN
cord-334973-jemeyudi	102	2	there	there	EX
cord-334973-jemeyudi	102	3	were	be	VBD
cord-334973-jemeyudi	102	4	no	no	DT
cord-334973-jemeyudi	102	5	deaths	death	NNS
cord-334973-jemeyudi	102	6	in	in	IN
cord-334973-jemeyudi	102	7	our	-PRON-	PRP$
cord-334973-jemeyudi	102	8	study	study	NN
cord-334973-jemeyudi	102	9	,	,	,
cord-334973-jemeyudi	102	10	many	many	JJ
cord-334973-jemeyudi	102	11	other	other	JJ
cord-334973-jemeyudi	102	12	studies	study	NNS
cord-334973-jemeyudi	102	13	have	have	VBP
cord-334973-jemeyudi	102	14	confirmed	confirm	VBN
cord-334973-jemeyudi	102	15	that	that	IN
cord-334973-jemeyudi	102	16	diabetes	diabetes	NN
cord-334973-jemeyudi	102	17	is	be	VBZ
cord-334973-jemeyudi	102	18	a	a	DT
cord-334973-jemeyudi	102	19	risk	risk	NN
cord-334973-jemeyudi	102	20	factor	factor	NN
cord-334973-jemeyudi	102	21	for	for	IN
cord-334973-jemeyudi	102	22	COVID-19	covid-19	JJ
cord-334973-jemeyudi	102	23	complications	complication	NNS
cord-334973-jemeyudi	102	24	and	and	CC
cord-334973-jemeyudi	102	25	increased	increase	VBN
cord-334973-jemeyudi	102	26	mortality	mortality	NN
cord-334973-jemeyudi	102	27	[	[	-LRB-
cord-334973-jemeyudi	102	28	2	2	CD
cord-334973-jemeyudi	102	29	,	,	,
cord-334973-jemeyudi	102	30	3	3	CD
cord-334973-jemeyudi	102	31	,	,	,
cord-334973-jemeyudi	102	32	5	5	CD
cord-334973-jemeyudi	102	33	]	]	-RRB-
cord-334973-jemeyudi	102	34	.	.	.
cord-334973-jemeyudi	103	1	There	there	EX
cord-334973-jemeyudi	103	2	is	be	VBZ
cord-334973-jemeyudi	103	3	no	no	DT
cord-334973-jemeyudi	103	4	specific	specific	JJ
cord-334973-jemeyudi	103	5	treatment	treatment	NN
cord-334973-jemeyudi	103	6	for	for	IN
cord-334973-jemeyudi	103	7	COVID-19	covid-19	NN
cord-334973-jemeyudi	103	8	now	now	RB
cord-334973-jemeyudi	103	9	,	,	,
cord-334973-jemeyudi	103	10	and	and	CC
cord-334973-jemeyudi	103	11	virus	virus	NN
cord-334973-jemeyudi	103	12	clearance	clearance	NN
cord-334973-jemeyudi	103	13	is	be	VBZ
cord-334973-jemeyudi	103	14	related	relate	VBN
cord-334973-jemeyudi	103	15	to	to	IN
cord-334973-jemeyudi	103	16	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	103	17	and	and	CC
cord-334973-jemeyudi	103	18	immune	immune	JJ
cord-334973-jemeyudi	103	19	function	function	NN
cord-334973-jemeyudi	103	20	,	,	,
cord-334973-jemeyudi	103	21	so	so	IN
cord-334973-jemeyudi	103	22	we	-PRON-	PRP
cord-334973-jemeyudi	103	23	can	can	MD
cord-334973-jemeyudi	103	24	provide	provide	VB
cord-334973-jemeyudi	103	25	patients	patient	NNS
cord-334973-jemeyudi	103	26	with	with	IN
cord-334973-jemeyudi	103	27	symptomatic	symptomatic	JJ
cord-334973-jemeyudi	103	28	and	and	CC
cord-334973-jemeyudi	103	29	support	support	NN
cord-334973-jemeyudi	103	30	treatment	treatment	NN
cord-334973-jemeyudi	103	31	,	,	,
cord-334973-jemeyudi	103	32	wait	wait	VB
cord-334973-jemeyudi	103	33	for	for	IN
cord-334973-jemeyudi	103	34	the	the	DT
cord-334973-jemeyudi	103	35	recovery	recovery	NN
cord-334973-jemeyudi	103	36	of	of	IN
cord-334973-jemeyudi	103	37	their	-PRON-	PRP$
cord-334973-jemeyudi	103	38	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	103	39	count	count	NN
cord-334973-jemeyudi	103	40	and	and	CC
cord-334973-jemeyudi	103	41	immune	immune	JJ
cord-334973-jemeyudi	103	42	function	function	NN
cord-334973-jemeyudi	103	43	,	,	,
cord-334973-jemeyudi	103	44	and	and	CC
cord-334973-jemeyudi	103	45	wait	wait	VB
cord-334973-jemeyudi	103	46	for	for	IN
cord-334973-jemeyudi	103	47	virus	virus	NN
cord-334973-jemeyudi	103	48	clearance	clearance	NN
cord-334973-jemeyudi	103	49	.	.	.
cord-334973-jemeyudi	104	1	Avoiding	avoid	VBG
cord-334973-jemeyudi	104	2	drugs	drug	NNS
cord-334973-jemeyudi	104	3	that	that	WDT
cord-334973-jemeyudi	104	4	impair	impair	VBP
cord-334973-jemeyudi	104	5	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	104	6	and	and	CC
cord-334973-jemeyudi	104	7	immune	immune	JJ
cord-334973-jemeyudi	104	8	function	function	NN
cord-334973-jemeyudi	104	9	may	may	MD
cord-334973-jemeyudi	104	10	be	be	VB
cord-334973-jemeyudi	104	11	beneficial	beneficial	JJ
cord-334973-jemeyudi	104	12	.	.	.
cord-334973-jemeyudi	105	1	Our	-PRON-	PRP$
cord-334973-jemeyudi	105	2	study	study	NN
cord-334973-jemeyudi	105	3	has	have	VBZ
cord-334973-jemeyudi	105	4	some	some	DT
cord-334973-jemeyudi	105	5	limitations	limitation	NNS
cord-334973-jemeyudi	105	6	.	.	.
cord-334973-jemeyudi	106	1	The	the	DT
cord-334973-jemeyudi	106	2	number	number	NN
cord-334973-jemeyudi	106	3	of	of	IN
cord-334973-jemeyudi	106	4	COVID-19	covid-19	JJ
cord-334973-jemeyudi	106	5	cases	case	NNS
cord-334973-jemeyudi	106	6	was	be	VBD
cord-334973-jemeyudi	106	7	small	small	JJ
cord-334973-jemeyudi	106	8	.	.	.
cord-334973-jemeyudi	107	1	There	there	EX
cord-334973-jemeyudi	107	2	were	be	VBD
cord-334973-jemeyudi	107	3	no	no	DT
cord-334973-jemeyudi	107	4	deaths	death	NNS
cord-334973-jemeyudi	107	5	in	in	IN
cord-334973-jemeyudi	107	6	our	-PRON-	PRP$
cord-334973-jemeyudi	107	7	study	study	NN
cord-334973-jemeyudi	107	8	.	.	.
cord-334973-jemeyudi	108	1	The	the	DT
cord-334973-jemeyudi	108	2	relationship	relationship	NN
cord-334973-jemeyudi	108	3	between	between	IN
cord-334973-jemeyudi	108	4	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	108	5	count	count	NN
cord-334973-jemeyudi	108	6	and	and	CC
cord-334973-jemeyudi	108	7	mortality	mortality	NN
cord-334973-jemeyudi	108	8	was	be	VBD
cord-334973-jemeyudi	108	9	not	not	RB
cord-334973-jemeyudi	108	10	observed	observe	VBN
cord-334973-jemeyudi	108	11	.	.	.
cord-334973-jemeyudi	109	1	We	-PRON-	PRP
cord-334973-jemeyudi	109	2	did	do	VBD
cord-334973-jemeyudi	109	3	not	not	RB
cord-334973-jemeyudi	109	4	obtain	obtain	VB
cord-334973-jemeyudi	109	5	data	datum	NNS
cord-334973-jemeyudi	109	6	of	of	IN
cord-334973-jemeyudi	109	7	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	109	8	subsets	subset	NNS
cord-334973-jemeyudi	109	9	and	and	CC
cord-334973-jemeyudi	109	10	could	could	MD
cord-334973-jemeyudi	109	11	not	not	RB
cord-334973-jemeyudi	109	12	analyze	analyze	VB
cord-334973-jemeyudi	109	13	the	the	DT
cord-334973-jemeyudi	109	14	decline	decline	NN
cord-334973-jemeyudi	109	15	in	in	IN
cord-334973-jemeyudi	109	16	specific	specific	JJ
cord-334973-jemeyudi	109	17	types	type	NNS
cord-334973-jemeyudi	109	18	of	of	IN
cord-334973-jemeyudi	109	19	lymphocytes	lymphocyte	NNS
cord-334973-jemeyudi	109	20	.	.	.
cord-334973-jemeyudi	110	1	This	this	DT
cord-334973-jemeyudi	110	2	research	research	NN
cord-334973-jemeyudi	110	3	was	be	VBD
cord-334973-jemeyudi	110	4	a	a	DT
cord-334973-jemeyudi	110	5	retrospective	retrospective	JJ
cord-334973-jemeyudi	110	6	study	study	NN
cord-334973-jemeyudi	110	7	,	,	,
cord-334973-jemeyudi	110	8	and	and	CC
cord-334973-jemeyudi	110	9	there	there	EX
cord-334973-jemeyudi	110	10	may	may	MD
cord-334973-jemeyudi	110	11	be	be	VB
cord-334973-jemeyudi	110	12	some	some	DT
cord-334973-jemeyudi	110	13	unknown	unknown	JJ
cord-334973-jemeyudi	110	14	confounding	confounding	JJ
cord-334973-jemeyudi	110	15	factors	factor	NNS
cord-334973-jemeyudi	110	16	in	in	IN
cord-334973-jemeyudi	110	17	the	the	DT
cord-334973-jemeyudi	110	18	study	study	NN
cord-334973-jemeyudi	110	19	.	.	.
cord-334973-jemeyudi	111	1	Basic	basic	JJ
cord-334973-jemeyudi	111	2	research	research	NN
cord-334973-jemeyudi	111	3	and	and	CC
cord-334973-jemeyudi	111	4	further	further	JJ
cord-334973-jemeyudi	111	5	clinical	clinical	JJ
cord-334973-jemeyudi	111	6	research	research	NN
cord-334973-jemeyudi	111	7	are	be	VBP
cord-334973-jemeyudi	111	8	still	still	RB
cord-334973-jemeyudi	111	9	needed	need	VBN
cord-334973-jemeyudi	111	10	to	to	TO
cord-334973-jemeyudi	111	11	determine	determine	VB
cord-334973-jemeyudi	111	12	whether	whether	IN
cord-334973-jemeyudi	111	13	the	the	DT
cord-334973-jemeyudi	111	14	mechanism	mechanism	NN
cord-334973-jemeyudi	111	15	of	of	IN
cord-334973-jemeyudi	111	16	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	111	17	count	count	NN
cord-334973-jemeyudi	111	18	decline	decline	NN
cord-334973-jemeyudi	111	19	in	in	IN
cord-334973-jemeyudi	111	20	patients	patient	NNS
cord-334973-jemeyudi	111	21	with	with	IN
cord-334973-jemeyudi	111	22	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	111	23	has	have	VBZ
cord-334973-jemeyudi	111	24	a	a	DT
cord-334973-jemeyudi	111	25	synergistic	synergistic	JJ
cord-334973-jemeyudi	111	26	effect	effect	NN
cord-334973-jemeyudi	111	27	with	with	IN
cord-334973-jemeyudi	111	28	immune	immune	JJ
cord-334973-jemeyudi	111	29	function	function	NN
cord-334973-jemeyudi	111	30	abnormalities	abnormality	NNS
cord-334973-jemeyudi	111	31	caused	cause	VBN
cord-334973-jemeyudi	111	32	by	by	IN
cord-334973-jemeyudi	111	33	diabetes	diabete	NNS
cord-334973-jemeyudi	111	34	.	.	.
cord-334973-jemeyudi	112	1	In	in	IN
cord-334973-jemeyudi	112	2	summary	summary	NN
cord-334973-jemeyudi	112	3	,	,	,
cord-334973-jemeyudi	112	4	COVID-19	covid-19	JJ
cord-334973-jemeyudi	112	5	patients	patient	NNS
cord-334973-jemeyudi	112	6	with	with	IN
cord-334973-jemeyudi	112	7	T2DM	T2DM	NNP
cord-334973-jemeyudi	112	8	experience	experience	VB
cord-334973-jemeyudi	112	9	a	a	DT
cord-334973-jemeyudi	112	10	faster	fast	JJR
cord-334973-jemeyudi	112	11	decline	decline	NN
cord-334973-jemeyudi	112	12	in	in	IN
cord-334973-jemeyudi	112	13	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	112	14	count	count	NN
cord-334973-jemeyudi	112	15	,	,	,
cord-334973-jemeyudi	112	16	have	have	VBP
cord-334973-jemeyudi	112	17	lower	low	JJR
cord-334973-jemeyudi	112	18	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	112	19	count	count	NN
cord-334973-jemeyudi	112	20	,	,	,
cord-334973-jemeyudi	112	21	and	and	CC
cord-334973-jemeyudi	112	22	longer	long	JJR
cord-334973-jemeyudi	112	23	hospital	hospital	NN
cord-334973-jemeyudi	112	24	stay	stay	NN
cord-334973-jemeyudi	112	25	than	than	IN
cord-334973-jemeyudi	112	26	non	non	JJ
cord-334973-jemeyudi	112	27	-	-	JJ
cord-334973-jemeyudi	112	28	diabetic	diabetic	JJ
cord-334973-jemeyudi	112	29	patients	patient	NNS
cord-334973-jemeyudi	112	30	.	.	.
cord-334973-jemeyudi	113	1	The	the	DT
cord-334973-jemeyudi	113	2	lower	low	JJR
cord-334973-jemeyudi	113	3	the	the	DT
cord-334973-jemeyudi	113	4	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	113	5	count	count	NN
cord-334973-jemeyudi	113	6	,	,	,
cord-334973-jemeyudi	113	7	the	the	DT
cord-334973-jemeyudi	113	8	longer	long	RBR
cord-334973-jemeyudi	113	9	the	the	DT
cord-334973-jemeyudi	113	10	hospitalization	hospitalization	NN
cord-334973-jemeyudi	113	11	time	time	NN
cord-334973-jemeyudi	113	12	and	and	CC
cord-334973-jemeyudi	113	13	viral	viral	JJ
cord-334973-jemeyudi	113	14	nucleic	nucleic	JJ
cord-334973-jemeyudi	113	15	acid	acid	NN
cord-334973-jemeyudi	113	16	positive	positive	JJ
cord-334973-jemeyudi	113	17	days	day	NNS
cord-334973-jemeyudi	113	18	.	.	.
cord-334973-jemeyudi	113	19	 	 	_SP
cord-334973-jemeyudi	114	1	Practical	practical	JJ
cord-334973-jemeyudi	114	2	recommendations	recommendation	NNS
cord-334973-jemeyudi	114	3	for	for	IN
cord-334973-jemeyudi	114	4	the	the	DT
cord-334973-jemeyudi	114	5	management	management	NN
cord-334973-jemeyudi	114	6	of	of	IN
cord-334973-jemeyudi	114	7	diabetes	diabete	NNS
cord-334973-jemeyudi	114	8	in	in	IN
cord-334973-jemeyudi	114	9	patients	patient	NNS
cord-334973-jemeyudi	114	10	with	with	IN
cord-334973-jemeyudi	114	11	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	114	12	Commentary	Commentary	NNP
cord-334973-jemeyudi	114	13	:	:	:
cord-334973-jemeyudi	115	1	COVID-19	covid-19	VB
cord-334973-jemeyudi	115	2	in	in	IN
cord-334973-jemeyudi	115	3	Patients	patient	NNS
cord-334973-jemeyudi	115	4	with	with	IN
cord-334973-jemeyudi	115	5	Diabetes	diabetes	NN
cord-334973-jemeyudi	115	6	Diabetes	diabetes	NN
cord-334973-jemeyudi	115	7	is	be	VBZ
cord-334973-jemeyudi	115	8	a	a	DT
cord-334973-jemeyudi	115	9	risk	risk	NN
cord-334973-jemeyudi	115	10	factor	factor	NN
cord-334973-jemeyudi	115	11	for	for	IN
cord-334973-jemeyudi	115	12	the	the	DT
cord-334973-jemeyudi	115	13	progression	progression	NN
cord-334973-jemeyudi	115	14	and	and	CC
cord-334973-jemeyudi	115	15	prognosis	prognosis	NN
cord-334973-jemeyudi	115	16	of	of	IN
cord-334973-jemeyudi	115	17	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	115	18	Clinical	Clinical	NNP
cord-334973-jemeyudi	115	19	Characteristics	Characteristics	NNPS
cord-334973-jemeyudi	115	20	of	of	IN
cord-334973-jemeyudi	115	21	Coronavirus	Coronavirus	NNP
cord-334973-jemeyudi	115	22	Disease	Disease	NNP
cord-334973-jemeyudi	115	23	2019	2019	CD
cord-334973-jemeyudi	115	24	in	in	IN
cord-334973-jemeyudi	115	25	China	China	NNP
cord-334973-jemeyudi	115	26	Clinical	Clinical	NNP
cord-334973-jemeyudi	115	27	course	course	NN
cord-334973-jemeyudi	115	28	and	and	CC
cord-334973-jemeyudi	115	29	risk	risk	NN
cord-334973-jemeyudi	115	30	factors	factor	NNS
cord-334973-jemeyudi	115	31	for	for	IN
cord-334973-jemeyudi	115	32	mortality	mortality	NN
cord-334973-jemeyudi	115	33	of	of	IN
cord-334973-jemeyudi	115	34	adult	adult	NN
cord-334973-jemeyudi	115	35	inpatients	inpatient	NNS
cord-334973-jemeyudi	115	36	with	with	IN
cord-334973-jemeyudi	115	37	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	115	38	in	in	IN
cord-334973-jemeyudi	115	39	Wuhan	Wuhan	NNP
cord-334973-jemeyudi	115	40	,	,	,
cord-334973-jemeyudi	115	41	China	China	NNP
cord-334973-jemeyudi	115	42	:	:	:
cord-334973-jemeyudi	116	1	a	a	DT
cord-334973-jemeyudi	116	2	retrospective	retrospective	JJ
cord-334973-jemeyudi	116	3	cohort	cohort	NN
cord-334973-jemeyudi	116	4	study	study	NN
cord-334973-jemeyudi	116	5	MHC	MHC	NNP
cord-334973-jemeyudi	116	6	Molecules	Molecules	NNPS
cord-334973-jemeyudi	116	7	,	,	,
cord-334973-jemeyudi	116	8	T	t	NN
cord-334973-jemeyudi	116	9	cell	cell	NN
cord-334973-jemeyudi	116	10	Receptors	receptor	NNS
cord-334973-jemeyudi	116	11	,	,	,
cord-334973-jemeyudi	116	12	Natural	Natural	NNP
cord-334973-jemeyudi	116	13	Killer	Killer	NNP
cord-334973-jemeyudi	116	14	Cell	Cell	NNP
cord-334973-jemeyudi	116	15	Receptors	Receptors	NNPS
cord-334973-jemeyudi	116	16	,	,	,
cord-334973-jemeyudi	116	17	and	and	CC
cord-334973-jemeyudi	116	18	Viral	Viral	NNP
cord-334973-jemeyudi	116	19	Immunoevasins	Immunoevasins	NNP
cord-334973-jemeyudi	116	20	-	-	HYPH
cord-334973-jemeyudi	116	21	Key	Key	NNP
cord-334973-jemeyudi	116	22	Elements	Elements	NNPS
cord-334973-jemeyudi	116	23	of	of	IN
cord-334973-jemeyudi	116	24	Adaptive	Adaptive	NNP
cord-334973-jemeyudi	116	25	and	and	CC
cord-334973-jemeyudi	116	26	Innate	Innate	NNP
cord-334973-jemeyudi	116	27	Immunity	immunity	NN
cord-334973-jemeyudi	117	1	The	the	DT
cord-334973-jemeyudi	117	2	impact	impact	NN
cord-334973-jemeyudi	117	3	of	of	IN
cord-334973-jemeyudi	117	4	macroautophagy	macroautophagy	NNS
cord-334973-jemeyudi	117	5	on	on	IN
cord-334973-jemeyudi	117	6	CD8(+	cd8(+	CD
cord-334973-jemeyudi	117	7	)	)	-RRB-
cord-334973-jemeyudi	118	1	T	t	NN
cord-334973-jemeyudi	118	2	-	-	HYPH
cord-334973-jemeyudi	118	3	cell	cell	NN
cord-334973-jemeyudi	118	4	-	-	HYPH
cord-334973-jemeyudi	118	5	mediated	mediate	VBN
cord-334973-jemeyudi	118	6	antiviral	antiviral	JJ
cord-334973-jemeyudi	118	7	immunity	immunity	NN
cord-334973-jemeyudi	118	8	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	118	9	pandemic	pandemic	NN
cord-334973-jemeyudi	118	10	,	,	,
cord-334973-jemeyudi	118	11	coronaviruses	coronaviruse	NNS
cord-334973-jemeyudi	118	12	,	,	,
cord-334973-jemeyudi	118	13	and	and	CC
cord-334973-jemeyudi	118	14	diabetes	diabetes	NN
cord-334973-jemeyudi	118	15	mellitus	mellitus	NN
cord-334973-jemeyudi	118	16	Reduction	Reduction	NNP
cord-334973-jemeyudi	118	17	and	and	CC
cord-334973-jemeyudi	118	18	Functional	functional	JJ
cord-334973-jemeyudi	118	19	Exhaustion	exhaustion	NN
cord-334973-jemeyudi	118	20	of	of	IN
cord-334973-jemeyudi	118	21	T	T	NNP
cord-334973-jemeyudi	118	22	Cells	cell	NNS
cord-334973-jemeyudi	118	23	in	in	IN
cord-334973-jemeyudi	118	24	Patients	patient	NNS
cord-334973-jemeyudi	118	25	With	with	IN
cord-334973-jemeyudi	118	26	Coronavirus	Coronavirus	NNP
cord-334973-jemeyudi	118	27	Disease	Disease	NNP
cord-334973-jemeyudi	118	28	2019	2019	CD
cord-334973-jemeyudi	118	29	(	(	-LRB-
cord-334973-jemeyudi	118	30	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	118	31	)	)	-RRB-
cord-334973-jemeyudi	118	32	.	.	.
cord-334973-jemeyudi	119	1	Front	Front	NNP
cord-334973-jemeyudi	119	2	Immunol	Immunol	NNP
cord-334973-jemeyudi	120	1	The	the	DT
cord-334973-jemeyudi	120	2	Diagnostic	Diagnostic	NNP
cord-334973-jemeyudi	120	3	Signifcance	Signifcance	NNP
cord-334973-jemeyudi	120	4	of	of	IN
cord-334973-jemeyudi	120	5	T	T	NNP
cord-334973-jemeyudi	120	6	Lymphocyte	Lymphocyte	NNP
cord-334973-jemeyudi	120	7	in	in	IN
cord-334973-jemeyudi	120	8	the	the	DT
cord-334973-jemeyudi	120	9	Early	Early	NNP
cord-334973-jemeyudi	120	10	Diagnosis	Diagnosis	NNP
cord-334973-jemeyudi	120	11	of	of	IN
cord-334973-jemeyudi	120	12	SARS	SARS	NNP
cord-334973-jemeyudi	120	13	.	.	.
cord-334973-jemeyudi	121	1	China	China	NNP
cord-334973-jemeyudi	121	2	Health	Health	NNP
cord-334973-jemeyudi	121	3	Standard	Standard	NNP
cord-334973-jemeyudi	121	4	Management	Management	NNP
cord-334973-jemeyudi	121	5	Characteristics	Characteristics	NNPS
cord-334973-jemeyudi	121	6	of	of	IN
cord-334973-jemeyudi	121	7	Peripheral	Peripheral	NNP
cord-334973-jemeyudi	121	8	Lymphocyte	Lymphocyte	NNP
cord-334973-jemeyudi	121	9	Subset	Subset	NNP
cord-334973-jemeyudi	121	10	Alteration	alteration	NN
cord-334973-jemeyudi	121	11	Lymphopenia	Lymphopenia	NNP
cord-334973-jemeyudi	121	12	in	in	IN
cord-334973-jemeyudi	121	13	severe	severe	JJ
cord-334973-jemeyudi	121	14	coronavirus	coronavirus	NN
cord-334973-jemeyudi	121	15	disease-2019	disease-2019	NNP
cord-334973-jemeyudi	121	16	(	(	-LRB-
cord-334973-jemeyudi	121	17	COVID-19	covid-19	NN
cord-334973-jemeyudi	121	18	)	)	-RRB-
cord-334973-jemeyudi	121	19	:	:	:
cord-334973-jemeyudi	121	20	systematic	systematic	JJ
cord-334973-jemeyudi	121	21	review	review	NN
cord-334973-jemeyudi	121	22	and	and	CC
cord-334973-jemeyudi	121	23	meta	meta	NNP
cord-334973-jemeyudi	121	24	-	-	HYPH
cord-334973-jemeyudi	121	25	analysis	analysis	NN
cord-334973-jemeyudi	121	26	Analysis	Analysis	NNP
cord-334973-jemeyudi	121	27	of	of	IN
cord-334973-jemeyudi	121	28	the	the	DT
cord-334973-jemeyudi	121	29	clinical	clinical	JJ
cord-334973-jemeyudi	121	30	characteristics	characteristic	NNS
cord-334973-jemeyudi	121	31	,	,	,
cord-334973-jemeyudi	121	32	drug	drug	NN
cord-334973-jemeyudi	121	33	treatments	treatment	NNS
cord-334973-jemeyudi	121	34	and	and	CC
cord-334973-jemeyudi	121	35	prognoses	prognosis	NNS
cord-334973-jemeyudi	121	36	of	of	IN
cord-334973-jemeyudi	121	37	136	136	CD
cord-334973-jemeyudi	121	38	patients	patient	NNS
cord-334973-jemeyudi	121	39	with	with	IN
cord-334973-jemeyudi	121	40	coronavirus	coronavirus	NN
cord-334973-jemeyudi	121	41	disease	disease	NN
cord-334973-jemeyudi	121	42	2019	2019	CD
cord-334973-jemeyudi	122	1	Lymphopenia	Lymphopenia	NNP
cord-334973-jemeyudi	122	2	is	be	VBZ
cord-334973-jemeyudi	122	3	associated	associate	VBN
cord-334973-jemeyudi	122	4	with	with	IN
cord-334973-jemeyudi	122	5	severe	severe	JJ
cord-334973-jemeyudi	122	6	coronavirus	coronavirus	NN
cord-334973-jemeyudi	122	7	disease	disease	NN
cord-334973-jemeyudi	122	8	2019	2019	CD
cord-334973-jemeyudi	122	9	(	(	-LRB-
cord-334973-jemeyudi	122	10	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	122	11	)	)	-RRB-
cord-334973-jemeyudi	122	12	infections	infection	NNS
cord-334973-jemeyudi	122	13	:	:	:
cord-334973-jemeyudi	123	1	A	a	DT
cord-334973-jemeyudi	123	2	systemic	systemic	JJ
cord-334973-jemeyudi	123	3	review	review	NN
cord-334973-jemeyudi	123	4	and	and	CC
cord-334973-jemeyudi	123	5	meta	meta	NNP
cord-334973-jemeyudi	123	6	-	-	HYPH
cord-334973-jemeyudi	123	7	analysis	analysis	NN
cord-334973-jemeyudi	124	1	Lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	124	2	subset	subset	NN
cord-334973-jemeyudi	124	3	(	(	-LRB-
cord-334973-jemeyudi	124	4	CD4	CD4	NNP
cord-334973-jemeyudi	124	5	+	+	CC
cord-334973-jemeyudi	124	6	,	,	,
cord-334973-jemeyudi	124	7	CD8	CD8	NNP
cord-334973-jemeyudi	124	8	+	+	CC
cord-334973-jemeyudi	124	9	)	)	-RRB-
cord-334973-jemeyudi	124	10	counts	count	NNS
cord-334973-jemeyudi	124	11	reflect	reflect	VBP
cord-334973-jemeyudi	124	12	the	the	DT
cord-334973-jemeyudi	124	13	severity	severity	NN
cord-334973-jemeyudi	124	14	of	of	IN
cord-334973-jemeyudi	124	15	infection	infection	NN
cord-334973-jemeyudi	124	16	and	and	CC
cord-334973-jemeyudi	124	17	predict	predict	VB
cord-334973-jemeyudi	124	18	the	the	DT
cord-334973-jemeyudi	124	19	clinical	clinical	JJ
cord-334973-jemeyudi	124	20	outcomes	outcome	NNS
cord-334973-jemeyudi	124	21	in	in	IN
cord-334973-jemeyudi	124	22	patients	patient	NNS
cord-334973-jemeyudi	124	23	with	with	IN
cord-334973-jemeyudi	124	24	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	124	25	Lymphocyte	Lymphocyte	NNP
cord-334973-jemeyudi	124	26	Subsets	subset	NNS
cord-334973-jemeyudi	124	27	Associated	Associated	NNP
cord-334973-jemeyudi	124	28	with	with	IN
cord-334973-jemeyudi	124	29	Prevalent	prevalent	JJ
cord-334973-jemeyudi	124	30	Diabetes	diabetes	NN
cord-334973-jemeyudi	124	31	in	in	IN
cord-334973-jemeyudi	124	32	Veterans	veteran	NNS
cord-334973-jemeyudi	124	33	with	with	IN
cord-334973-jemeyudi	124	34	and	and	CC
cord-334973-jemeyudi	124	35	without	without	IN
cord-334973-jemeyudi	124	36	HIV	HIV	NNP
cord-334973-jemeyudi	124	37	Peripheral	Peripheral	NNP
cord-334973-jemeyudi	124	38	lymphocyte	lymphocyte	NN
cord-334973-jemeyudi	124	39	subset	subset	NN
cord-334973-jemeyudi	124	40	of	of	IN
cord-334973-jemeyudi	124	41	patients	patient	NNS
cord-334973-jemeyudi	124	42	with	with	IN
cord-334973-jemeyudi	124	43	pancreatic	pancreatic	JJ
cord-334973-jemeyudi	124	44	diabetes	diabetes	NN
cord-334973-jemeyudi	124	45	mellitus	mellitus	NN
cord-334973-jemeyudi	124	46	--	--	:
cord-334973-jemeyudi	124	47	about	about	IN
cord-334973-jemeyudi	124	48	a	a	DT
cord-334973-jemeyudi	124	49	decreased	decrease	VBN
cord-334973-jemeyudi	124	50	ratio	ratio	NN
cord-334973-jemeyudi	124	51	of	of	IN
cord-334973-jemeyudi	124	52	T	T	NNP
cord-334973-jemeyudi	124	53	-	-	HYPH
cord-334973-jemeyudi	124	54	LGL	lgl	NN
cord-334973-jemeyudi	124	55	and	and	CC
cord-334973-jemeyudi	124	56	ability	ability	NN
cord-334973-jemeyudi	124	57	of	of	IN
cord-334973-jemeyudi	124	58	host	host	NN
cord-334973-jemeyudi	124	59	defense	defense	NN
cord-334973-jemeyudi	124	60	Receptor	Receptor	NNP
cord-334973-jemeyudi	124	61	Recognition	Recognition	NNP
cord-334973-jemeyudi	124	62	by	by	IN
cord-334973-jemeyudi	124	63	the	the	DT
cord-334973-jemeyudi	124	64	Novel	Novel	NNP
cord-334973-jemeyudi	124	65	Coronavirus	Coronavirus	NNP
cord-334973-jemeyudi	124	66	from	from	IN
cord-334973-jemeyudi	124	67	Wuhan	Wuhan	NNP
cord-334973-jemeyudi	124	68	:	:	:
cord-334973-jemeyudi	124	69	an	an	DT
cord-334973-jemeyudi	124	70	Analysis	Analysis	NNP
cord-334973-jemeyudi	124	71	Based	base	VBN
cord-334973-jemeyudi	124	72	on	on	IN
cord-334973-jemeyudi	124	73	Decade	decade	NN
cord-334973-jemeyudi	124	74	-	-	HYPH
cord-334973-jemeyudi	124	75	Long	Long	NNP
cord-334973-jemeyudi	124	76	Structural	Structural	NNP
cord-334973-jemeyudi	124	77	Studies	Studies	NNPS
cord-334973-jemeyudi	124	78	of	of	IN
cord-334973-jemeyudi	124	79	SARS	SARS	NNP
cord-334973-jemeyudi	124	80	Coronavirus	Coronavirus	NNP
cord-334973-jemeyudi	125	1	Are	be	VBP
cord-334973-jemeyudi	125	2	patients	patient	NNS
cord-334973-jemeyudi	125	3	with	with	IN
cord-334973-jemeyudi	125	4	hypertension	hypertension	NN
cord-334973-jemeyudi	125	5	and	and	CC
cord-334973-jemeyudi	125	6	diabetes	diabetes	NN
cord-334973-jemeyudi	125	7	mellitus	mellitus	NN
cord-334973-jemeyudi	125	8	at	at	IN
cord-334973-jemeyudi	125	9	increased	increase	VBN
cord-334973-jemeyudi	125	10	risk	risk	NN
cord-334973-jemeyudi	125	11	for	for	IN
cord-334973-jemeyudi	125	12	COVID-19	COVID-19	NNP
cord-334973-jemeyudi	125	13	infection	infection	NN
cord-334973-jemeyudi	125	14	Differential	differential	JJ
cord-334973-jemeyudi	125	15	virological	virological	JJ
cord-334973-jemeyudi	125	16	and	and	CC
cord-334973-jemeyudi	125	17	immunological	immunological	JJ
cord-334973-jemeyudi	125	18	outcome	outcome	NN
cord-334973-jemeyudi	125	19	of	of	IN
cord-334973-jemeyudi	125	20	severe	severe	JJ
cord-334973-jemeyudi	125	21	acute	acute	JJ
cord-334973-jemeyudi	125	22	respiratory	respiratory	JJ
cord-334973-jemeyudi	125	23	syndrome	syndrome	NN
cord-334973-jemeyudi	125	24	coronavirus	coronavirus	NN
cord-334973-jemeyudi	125	25	infection	infection	NN
cord-334973-jemeyudi	125	26	in	in	IN
cord-334973-jemeyudi	125	27	susceptible	susceptible	JJ
cord-334973-jemeyudi	125	28	and	and	CC
cord-334973-jemeyudi	125	29	resistant	resistant	JJ
cord-334973-jemeyudi	125	30	transgenic	transgenic	JJ
cord-334973-jemeyudi	125	31	mice	mouse	NNS
cord-334973-jemeyudi	125	32	expressing	express	VBG
cord-334973-jemeyudi	125	33	human	human	JJ
cord-334973-jemeyudi	125	34	angiotensin	angiotensin	NN
cord-334973-jemeyudi	125	35	-	-	HYPH
cord-334973-jemeyudi	125	36	converting	convert	VBG
cord-334973-jemeyudi	125	37	enzyme	enzyme	NN
cord-334973-jemeyudi	125	38	2	2	CD
cord-334973-jemeyudi	125	39	Diabetes	diabetes	NN
cord-334973-jemeyudi	125	40	and	and	CC
cord-334973-jemeyudi	125	41	COVID-19	covid-19	NN
cord-334973-jemeyudi	125	42	:	:	:
cord-334973-jemeyudi	125	43	evidence	evidence	NN
cord-334973-jemeyudi	125	44	,	,	,
cord-334973-jemeyudi	125	45	current	current	JJ
cord-334973-jemeyudi	125	46	status	status	NN
cord-334973-jemeyudi	125	47	and	and	CC
cord-334973-jemeyudi	125	48	unanswered	unanswered	JJ
cord-334973-jemeyudi	125	49	research	research	NN
cord-334973-jemeyudi	125	50	questions	question	NNS
cord-334973-jemeyudi	126	1	Data	datum	NNS
cord-334973-jemeyudi	126	2	are	be	VBP
cord-334973-jemeyudi	126	3	reported	report	VBN
cord-334973-jemeyudi	126	4	as	as	IN
cord-334973-jemeyudi	126	5	mean	mean	JJ
cord-334973-jemeyudi	126	6	±	±	NNP
cord-334973-jemeyudi	126	7	SD	SD	NNP
cord-334973-jemeyudi	126	8	,	,	,
cord-334973-jemeyudi	126	9	median	median	NN
cord-334973-jemeyudi	126	10	(	(	-LRB-
cord-334973-jemeyudi	126	11	IQR	IQR	NNP
cord-334973-jemeyudi	126	12	)	)	-RRB-
cord-334973-jemeyudi	126	13	or	or	CC
cord-334973-jemeyudi	126	14	number	number	NN
cord-334973-jemeyudi	126	15	and	and	CC
cord-334973-jemeyudi	126	16	percentage	percentage	NN
cord-334973-jemeyudi	126	17	.	.	.
cord-334973-jemeyudi	127	1	BMI	BMI	NNP
cord-334973-jemeyudi	127	2	,	,	,
cord-334973-jemeyudi	127	3	body	body	NN
cord-334973-jemeyudi	127	4	mass	mass	NN
cord-334973-jemeyudi	127	5	index	index	NN
cord-334973-jemeyudi	127	6	;	;	:
cord-334973-jemeyudi	127	7	SBP	SBP	NNP
cord-334973-jemeyudi	127	8	,	,	,
cord-334973-jemeyudi	127	9	systolic	systolic	JJ
cord-334973-jemeyudi	127	10	blood	blood	NN
cord-334973-jemeyudi	127	11	pressure	pressure	NN
cord-334973-jemeyudi	127	12	WBC	WBC	NNP
cord-334973-jemeyudi	127	13	,	,	,
cord-334973-jemeyudi	127	14	white	white	JJ
cord-334973-jemeyudi	127	15	blood	blood	NN
cord-334973-jemeyudi	127	16	cell	cell	NN
cord-334973-jemeyudi	127	17	Multivariable	multivariable	JJ
cord-334973-jemeyudi	127	18	regression	regression	NN
cord-334973-jemeyudi	127	19	model	model	NN
cord-334973-jemeyudi	127	20	was	be	VBD
cord-334973-jemeyudi	127	21	used	use	VBN
cord-334973-jemeyudi	127	22	to	to	TO
cord-334973-jemeyudi	127	23	adjust	adjust	VB
cord-334973-jemeyudi	127	24	for	for	IN
cord-334973-jemeyudi	127	25	potential	potential	JJ
cord-334973-jemeyudi	127	26	confounding	confounding	JJ
cord-334973-jemeyudi	127	27	factors	factor	NNS
cord-334973-jemeyudi	127	28	including	include	VBG
cord-334973-jemeyudi	127	29	age	age	NN
cord-334973-jemeyudi	127	30	,	,	,
cord-334973-jemeyudi	127	31	gender	gender	NN
cord-334973-jemeyudi	127	32	Multivariable	multivariable	JJ
cord-334973-jemeyudi	127	33	regression	regression	NN
cord-334973-jemeyudi	127	34	model	model	NN
cord-334973-jemeyudi	127	35	was	be	VBD
cord-334973-jemeyudi	127	36	used	use	VBN
cord-334973-jemeyudi	127	37	to	to	TO
cord-334973-jemeyudi	127	38	adjust	adjust	VB
cord-334973-jemeyudi	127	39	for	for	IN
cord-334973-jemeyudi	127	40	potential	potential	JJ
cord-334973-jemeyudi	127	41	confounding	confounding	JJ
cord-334973-jemeyudi	127	42	factors	factor	NNS
cord-334973-jemeyudi	127	43	including	include	VBG
cord-334973-jemeyudi	127	44	age	age	NN
cord-334973-jemeyudi	127	45	,	,	,
cord-334973-jemeyudi	127	46	gender	gender	NN
cord-334973-jemeyudi	128	1	This	this	DT
cord-334973-jemeyudi	128	2	research	research	NN
cord-334973-jemeyudi	128	3	did	do	VBD
cord-334973-jemeyudi	128	4	not	not	RB
cord-334973-jemeyudi	128	5	receive	receive	VB
cord-334973-jemeyudi	128	6	any	any	DT
cord-334973-jemeyudi	128	7	specific	specific	JJ
cord-334973-jemeyudi	128	8	grant	grant	NN
cord-334973-jemeyudi	128	9	from	from	IN
cord-334973-jemeyudi	128	10	funding	fund	VBG
cord-334973-jemeyudi	128	11	agencies	agency	NNS
cord-334973-jemeyudi	128	12	in	in	IN
cord-334973-jemeyudi	128	13	the	the	DT
cord-334973-jemeyudi	128	14	public	public	NN
cord-334973-jemeyudi	128	15	,	,	,
cord-334973-jemeyudi	128	16	commercial	commercial	JJ
cord-334973-jemeyudi	128	17	,	,	,
cord-334973-jemeyudi	128	18	or	or	CC
cord-334973-jemeyudi	128	19	not	not	RB
cord-334973-jemeyudi	128	20	-	-	HYPH
cord-334973-jemeyudi	128	21	for	for	IN
cord-334973-jemeyudi	128	22	-	-	HYPH
cord-334973-jemeyudi	128	23	profit	profit	NN
cord-334973-jemeyudi	128	24	sectors	sector	NNS
cord-334973-jemeyudi	128	25	.	.	.
cord-334973-jemeyudi	129	1	All	all	DT
cord-334973-jemeyudi	129	2	authors	author	NNS
cord-334973-jemeyudi	129	3	declare	declare	VBP
cord-334973-jemeyudi	129	4	no	no	DT
cord-334973-jemeyudi	129	5	conflict	conflict	NN
cord-334973-jemeyudi	129	6	of	of	IN
cord-334973-jemeyudi	129	7	interest	interest	NN
cord-334973-jemeyudi	129	8	.	.	.